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Enantioselektiva Michael additionsreaktioner av α-substituerade fenylpropanoater till 
akrylnitriler samt enantioselektiva Michael additionsreaktioner av bensyl cyanider till 
akrylater utfördes med hjälp av fas-överförings katalysatorer. Användning av 
dimeriska Cinchona-alkaloid derivat som katalysatorer (5 mol-%) i Michael 
additionsreaktionen av α-metylbensyl cyanid till etyl akrylat under milda 
reaktionsbetingelser gav produkten med ett enantiomeriskt överskott upp till 28% ee. 
Ett antal Cinchona-alkaloid härledda katalysatorer utvärderades liksom även andra 
katalysatorer så som Ooi och kollegers kirala tetraaminofosfonium salter och 
pentanidium saltet utvecklat av Tan och medarbetare. Olyckligtvis var produkterna 
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bensylcinkonidinium bromid (5 mol-%) i Michael additionsreaktionen av α-
isopropylbensyl cyanid till etylakrylat under milda reaktionsbetingelser gav produkten 
med ett enantiomerisk överskott på upp till 30% ee. 
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1. Introduction 
In 1971 Charles M. Starks first coined the term “phase-transfer catalysis”. This term 
described a solution to the heterogeneity problem that arises when substances of a 
reaction are in different phases of the reaction mixture. Traditionally this problem was 
solved by issuing an appropriate mutual solvent, but by adding a small quantity of an 
agent which transfers one reactant across the interface into the other, the reaction 
can proceed smoothly even in the case of heterogeneous phase systems. Starks 
found that organic-soluble quaternary ammonium or phosphonium cations, Q+, were 
suitable agents for the transport of anions from the aqueous phase to the organic 
phase (Figure 1). [1]  
 
Figure 1. Illustration of phase-transfer catalysis (Starks extraction mechanism).  
The focus in phase-transfer catalysis has mainly been on structures such as protected 
prochiral glycine derivatives and malonates, and less attention has been paid to 
substrates with a higher pKa [2]. To the best of my knowledge the type of reaction 
which is aimed for in this thesis (Scheme 1) has only been successfully performed 
chirally by using chiral crown ethers [3]. Since all research that addresses this type of 
phase-transfer catalysis is from the beginning of the 1980’s to early 1990’s, it would 
be preferable to evaluate the categories of catalysts that have been developed since 
then. 
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Scheme 1. Generating new stereocenters via chiral phase-transfer catalysis. 
The method that is aimed to be developed could possibly enable the synthesis of the 
neurokinin 3 receptor antagonist Osanetant, the L-type calcium channel blocker (S)-
Verapamil and the opioid analgesic Profadol (Figure 2). 
 
Figure 2. The structure of possible structures containing the stereocenter aimed 
for. 
This thesis aims to develop a method generating new stereocenters via chiral phase-
transfer catalysis. This involves choosing the starting material, finding the optimal 
catalyst and optimization of reaction conditions such as solvent, temperature and 
base. 
This thesis is divided into six chapters. Chapter 2 gives an overview of catalysts used 
for phase-transfer catalysis while chapter 3 will analyze phase-transfer catalyzed 
Michael additions. Chapters 4 and 5 summarize the experimental part of the thesis. 
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2. Evolution of phase-transfer catalysts 
Though Stark was the first to coin the term “phase-transfer catalysis”, he was not 
alone in setting the foundation for the method. Reports that some quaternary 
compounds assist in carbanion reactions in the presence of aqueous alkali hydroxides 
in two-phase systems had appeared already in the early 50’s. The foundations for 
phase-transfer catalysis were essentially a combination of the work started by 
Makosza in the mid-60s, and the input by Brändström and Stark in the 70’s. [4] 
Two mechanisms have been suggested for hydroxide-initiated phase-transfer-
catalysis to explain the activity of the catalyst. The first mechanism is the one 
mentioned in the introduction, namely the extraction mechanism suggested by Stark 
[1] (Figure 3, left) and the second one is the interfacial mechanism proposed by 
Makosza [5] (Figure 3, right). The extraction mechanism suggests that a quaternary 
ammonium species (Q+) acts to transfer the hydroxide ion to the organic phase to 
generate the ammonium enolate (Q+En-) [1]. In the interfacial mechanism it is 
suggested that the enolate is formed at the interfacial region between the organic 
phase and the aqueous phase by the action of the hydroxide ion. The newly formed 
carbanion will subsequently form an organic phase soluble ion-pair with the cation 
supplied by catalyst. [5]  
 
Figure 3. Left: the extraction mechanism; Right: the interfacial mechanism. En- 
= enolate [6] 
Numerous kinetic studies have supported both of these mechanisms, depending on 
reaction conditions. A general guideline is that phase-transfer catalyzed reactions of 
carbon acids follow the interfacial mechanism when the carbon acid is within a pKa 
range of 18 to 25. [6] Bordwell’s collection of pKa values for substances similar to the 
starting materials in this literary review is provided below (Table 1) [7]. 
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Table 1. Bordwell pKa values (acidity in DMSO). 
 
2.1. Cinchona alkaloid derived catalysts 
In 1984 the discovery by a Merck research group created a noticeably boost in the 
field of phase-transfer catalysis. Merck researchers succeeded in executing an 
enantioselective alkylation by using a chiral catalyst in their asymmetric synthesis of 
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uricosuric (+)-indacrinone (Scheme 2). The aforementioned chiral catalyst used in this 
reaction was N-(p-trifluoromethyl)benzylcinchoninium bromide (catalyst 22a) [8, 2]. 
 
Scheme 2. The Merck group’s enantioselective alkylation synthesis. 
It has been found that two characteristics benefit the paring cation (Q+) the most; 
being organically soluble and having a large ionic radius, thus improving the 
displacement rate [1]. This is also why ammonium and phosphonium salts have 
become so popular in phase-transfer catalysis. Especially in the chiral catalyst array, 
catalysts derived from Chinchona alkaloids have been popular study targets. [2] Other 
than having the beneficial characteristics of a good phase-transfer catalyst, they are 
also usually inexpensive and the tertiary amine and/or the secondary alcohol in the 
catalyst can be modified to bring more bulk or electronic effect to the catalyst. In 
addition, both enantiomers can potentially be prepared by interchanging the catalyst 
from a cinchonine-based to a cinchonidine-based catalyst series. This property was 
observed for the first time in a study performed by O’Donnell and co-workers in 1989, 
when catalysts 24a and 24b were discovered to be enantio-complimentary in the 
sense that they led to selectivity for the opposite enantiomers of the product. The 
chiral phase-transfer catalysts in question were used for the first asymmetric alkylation 
of glycine imine ester 2 (Scheme 3). The reactions were successfully carried out with 
N-benzyl derivatives of the Cinchona alkaloids cinchonidine and cinchonine as phase-
transfer catalysts. [9] 
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Scheme 3. The asymmetric synthesis path of O’Donnell and co-workers. 
A significant challenge in the alkylation of a prochiral substrate is to obtain a product 
that has only been alkylated once. In the reaction above, the substrate is only 
alkylated once because of the sufficiently lower acidity of the remaining α-proton. As 
will be discernable in the literary review part of this thesis, protected prochiral glycine 
derivatives have been very popular substrates in phase-transfer catalysis. Together 
with a chiral catalyst, protected prochiral glycine derivatives create an attractive 
method for the preparation of optically active α-amino acids. In the above mentioned 
study, O’Donnell and co-workers found that the tert-butyl ester Schiff base 2 gave the 
best results in the substrate scope [9].  
The next significant progress in the development of Cinchona alkaloid derived phase-
transfer catalysis was the creation of a new generation of Cinchona derived catalysts. 
Lygo and co-workers created N-anthracenylmethylammonium salts 3a and 3b in 
1997. They utilized the new catalysts in the same reaction as O’Donnell, with slight 
variation in the reaction conditions (Scheme 4). [10] 
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Scheme 4. The asymmetric synthesis path of Lygo and co-workers. 
At the same time as Lygo and co-workers reported their N-anthracenyl-
methylammonium salts, Corey and co-workers introduced another catalyst in this 
category. However, for their synthesis they used caesium hydroxide monohydrate as 
the base to minimize the amount of water in the organic phase and allow the use of 
temperatures lower than those  possible with a 50% aqueous NaOH or KOH solution 
(Scheme 5) [11]. In connection to their previous study on bis-Cinchona alkaloid 
catalysts they found that when attached to a quaternary ammonium structure with a 
defined geometry, like in the case of cinchonidine, the 9-anthracenylmethyl group 
blocks the second tetrahedral face of the positively charged nitrogen [12]. 
 
Scheme 5. The asymmetric synthesis path of Corey and co-workers. 
During the development of the asymmetric Sharpless dihydroxylation, it was 
discovered that ligands with two independent Cinchona alkaloid units attached to 
heterocyclic spacers (for example a phthalazine core or diphenylpyrimidine core [13]) 
led to considerable enhancement in enantioselectivity and increased the substrate 
scope. [14] Inspired by the discovery of the positive influence of a bulky subunit such 
as the anthracenyl-group and the dimerization effect in the asymmetric Sharpless 
dihydroxylation, Jew, Park and co-workers decided to study the effect of dimeric 
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catalysts. The most successful catalysts are gathered below. (Scheme 6) [15, 16, 17, 
18] 
 
Scheme 6. Dimeric catalysts created by Jew, Park and co-workers. 
Other groups have also shown interest for the effect on reactions catalyzed by dimeric 
catalysts, such as Nájera and co-workers, but since the catalysts they studied 
(dimethylanthracenyl bridged dimeric compounds) are not utilized in this thesis, they 
will not be covered in this literature review part of the thesis. 
Jew, Park and co-workers also decided to study the electronic effect of aromatic 
fluorines on phase-transfer catalysts in 2002 (Scheme 7). 
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Scheme 7. The electronic effect of fluorine atoms on the enantioselectivity. 
The group expected the electron-withdrawing functional groups to increase the 
enantioselectivity by the formation of a tighter binding ion pair, which would lead to a 
more rigid conformation. Unfortunately the results did not support this theory, at least 
not in the case of meta- or para-substitution. Ortho substitution did seem to marginally 
enhance the enantioselectivity. [19]  
Jew and co-workers were encouraged by the results for the electron withdrawing 
effect caused by ortho-substituted catalysts and decided to further study the electronic 
effect by adding electron withdrawing groups solely at the ortho-position (Scheme 8).  
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Scheme 8. Using electron withdrawing groups to enhance the enantioselectivity. 
They proposed that the high enantioselectivity might be due to electronic interactions 
involving water between the oxygen at C(9) and an electronegative group such as 2’-
CN in the catalyst. Hydrogen bonding or an induced dipole-dipole interaction, for 
example, would therefore give the catalyst a more rigid conformation. [20] 
2.2. Non-Cinchona derived catalysts 
Chiral spiro ammonium salts 
The next step in the development of phase-transfer catalysts was the creation of chiral 
spiroammonium salts, like the ones developed by Maruoka and co-workers in 1999. 
They sought a non-Cinchona alkaloid derivative that could be rationally designed and 
fine-tuned to suit their reactions. They initiated the search for such a catalyst by using 
commercially available (S)-binaphthol as the chiral unit of the spiroammonium salt 
(Scheme 9). [21] 
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Scheme 9. First generation of C2-symmetric chiral quaternary ammonium salts 
created by Maruoka and co-workers. 
The results from the reaction above prompted the group to create a structurally more 
rigid chiral spiroammonium salt. By varying the aromatic substituent at the 3,3’ 
position at one of the binaphthyl subunits of the catalyst, the enantiofacial 
discrimination could be varied. [21,22] The best results were achieved by varying the 
aromatic substituents, and are gathered below (Scheme 10). 
 
Scheme 10. Second generation of C2-symmetric chiral quaternary ammonium salts 
created by Maruoka and co-workers. 
Maruoka and co-workers discovered in 2005 that by adding a fluoro-substituted 
phenyl ring to the binaphthyl unit and changing the aromatic ammonium substituents 
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for hydrocarbon chains, the enantioselectivity could be increased trifold compared to 
the first generation catalysts (Scheme 10) [23]. 
 
Scheme 11. Improved first generation Maruoka catalyst. 
Maruoka further decided to improve the catalyst series by expanding the chiral 
environment and by varying the second unit in the catalyst. A few examples of these 
variations are presented below (Scheme 12). [24,25]  
 
Scheme 12. Variations of the chiral quaternary ammonium salts created by 
Maruoka and co-workers. 
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Tetraaminophosphonium salts 
Ooi and co-workers decided to create their own catalyst series using chiral 
tetraaminophosphonium chloride for use in asymmetric phase-transfer. The structure 
of the chiral tetraaminophosphonium chloride (cat. 45) from which the development 
began was readily synthesized from the parent α-amino acid, L-valine (Figure 4). [26]  
 
Figure 4. Development of chiral tetraaminophosphonium chloride. 
This catalyst was then used in the asymmetric direct Henry reaction of nitroalkanes 
to benzaldehydes (Scheme 13). [26] 
 
Scheme 13. Chiral tetraaminophosphonium salt mediated asymmetric Henry 
reaction of nitroalkanes to benzaldehydes. 
The next step in the development of their chiral catalyst family was tuning the basicity 
of the anionic component. In 2008 it was attempted by using carboxylates as the anion 
part of the salt (Scheme 14). [27] 
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Scheme 14. Chiral tetraaminophosphonium carboxylate-catalyzed direct Mannich-
type reaction. 
The following year they decided to tune the anionic part of the salt in the following way 
(Scheme 15) [28]:  
 
Scheme 15. Chiral tetraaminophosphonium phenoxide-catalyzed reaction. 
The single-crystal X-ray diffraction analysis of the solid state structure of the salt with 
the anionic component 55∙(OPh)3H2 revealed that the aminophosphonium cation, 
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together with the two phenols and the phenoxide anion was aligned through a 10-
membered cyclic network of intermolecular hydrogen-bonding interactions. Ooi 
hypothesized that the additional hydrogen bond from N-H protons in the phosphonium 
cation enhances the hydrogen bonding donor capability of the phenols, thus aiding 
the construction of an antidromic circular network. In addition, it is believed that the 
phenols effectively relay the stereochemical information in the chiral cation moiety, 
thus extending the chiral environment around the remotely located phenoxide anion. 
[28] 
When the order of additions in the reaction was examined, the results indicated that 
the preorganization of the catalyst is not a prerequisite for the generation of the 
catalyst-substrate complex. These results implied that the selectivity could be tunable 
through structural modification of the achiral phenolic component. The role of a 
requisite molecular assembly was also supported when Ooi and co-workers 
succeeded in improving the enantioselectivity by increasing the catalyst loading and 
decreasing the solvent volume. [28]  
In 2011, Ooi and co-workers used 31P NMR spectroscopy to measure the structure of 
catalyst 55∙(OPh)3H2 in solution. In connection to the measurement, they found a 
phenomenon regarding the mode of molecular association. There seems to be three 
possible molecular assemblies in solution, which can easily be adjusted by adjusting 
the stoichiometry of the anionic component of catalyst 55.(OPh)nH(n-1) (Figure 5). [29] 
 
Figure 5. Equilibrium between molecular assemblies. 
Each of the above mentioned assembly has been confirmed by x-ray crystallographic 
analysis of the solid state. It seems that n=3 is the maximum amount in the molecular 
association. The number of anionic components incorporated in the catalyst assembly 
affects the enantioselectivity, however, the increase of the enantioselectivity between 
n = 2 and n = 3 is minimal (Scheme 16). [29] 
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Scheme 16. Asymmetric conjugate addition catalyzed by chiral tetraamino-
phosphonium aryloxide assemblies. 
In 2009, the group created another chiral tetraaminophosphonium salt, prepared this 
time from the commercially available (R,R)-1,2-diphenylethylenediamide In the study 
they aimed at developing a method for the incorporation of a variety of chiral, 
nonracemic, quaternary α-amino acids as specific sites of a peptide strand using their 
new catalyst (Scheme 17). [30] 
 
Scheme 17. Chiral tetraaminophosphonium chloride catalyzed alkylation of an 
azlactone. 
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Other chiral catalysts 
Other interesting catalysts are for example the chiral copper-salen complex 66 
reported by Belokon and co-workers (Scheme 18) [31]. 
 
Scheme 18. Copper-salen complex catalyzed alkylation reported by Belokon and 
co-workers. 
Their idea for this catalyst came from their studies utilizing TADDOL (α,α,α,α-tetraaryl-
1,3-dioxolane-4,5- dimethanols) and NOBIN (2-amino-2'-hydroxy-1,1'-binaphthyl) as 
the chelating agent for the alkali ions, making the ion-pair of the corresponding 
carbanion and alkali ion soluble in organic solvents (Scheme 19). They then decided 
to combine the synthetic simplicity of the phase-transfer catalysis with the advantages 
of catalysis by metal complexes in their study of the chiral copper-salen complex 66. 
[32, 33] 
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Scheme 19. TADDOL and NOBIN catalyzed phase-transfer catalysis. 
Shibasaki and co-workers approached the creation of their own catalyst by first 
performing a molecular mechanics simulation using the Monte Carlo method. The 
results suggested that the Schiff base of tert-butyl glycinate would place itself between 
both ammonium cations of the catalyst in the way the group had hoped. They then 
proceeded with synthesizing a variety of catalysts from L- and D-tartrate, varying the 
ketal moieties and the aromatic parts (Scheme 20). [34] 
 
Scheme 20. Asymmetric phase-transfer alkylation utilizing the two-center tartrate 
catalyst by Shibasaki and co-workers. 
Takabe and co-workers also attempted to create their own catalyst series. They 
prepared the C3-symmetric amine-based chiral phase-transfer catalyst 73 presented 
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below (Scheme 21). Takabe and co-workers attributed the enantioselectivity to the 
hydrogen bonding between one of the chiral hydroxyl groups and the nitrogen in the 
Schiff base. [35] However, neither the yield nor the enantioselectivity was especially 
good, which might be attributed to the flexibleness of the catalyst.  
 
Scheme 21. Asymmetric phase-transfer alkylation utilizing a C3-symmetric amine 
based chiral phase-transfer catalyst. 
Nagasawa and co-workers used a C2-symmetric chiral cyclic guanidine catalyst 74 in 
their asymmetric alkylation of a Schiff base (Scheme 22). They found that the methyl 
substituent was crucial for enantiomeric enhancement. 
 
Scheme 22. Asymmetric phase-transfer alkylation utilizing a C2-symmetric chiral 
cyclic guanidine catalyst. 
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3. Michael addition 
Conjugate addition is synthetically a most versatile bond forming strategy (Scheme 
23). This is mainly due to the broad spectrum of donors (nucleophiles) and acceptors 
(alkenes and alkynes attached to an electron withdrawing group (EWG)). The 
nucleophile can be carbon or heteroatom based, and the diversity in acceptors arises 
from the broad variety of activating EWG groups (ketones, aldehydes, esters, amide, 
nitriles, nitro, sulfones, sulfoxides, phosphates etc.) 
 
Scheme 23. The 1,4-addition of resonance stabilized carbanions. 
In the late nineteenth century (1887) Arthur Michael found that the enolate anion 
derived from diethyl malonate reacts with ethyl cinnamate at the β-carbon to give the 
enolate anion as the product (Scheme 24) [36]. The two stage mechanism (addition 
followed by protonation) is preceded by first deprotonating the nucleophile by a base 
to form a resonance stabilized carbanion that can react with the ethyl cinnamate. 
 
Scheme 24. The reaction of Arthur Michael. 
Since then, many strategies for controlling the stereochemistry of the product have 
been developed. The first reported Michael type reaction utilizing a chiral catalyst was 
reported by Göran Bergson and Bengt Långström in 1973 (Scheme 25). [37] 
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Scheme 25.  First chiral catalyzed Michael-type reaction. 
Michael addition has also been utilized in phase-transfer catalysis. The first successful 
Michael addition under phase-transfer conditions was accomplished by Cram and 
Sogah in 1981. Inspired by the results obtained by Bergson and Långström, Cram 
and Sogah decided to perform a similar reaction, but under phase-transfer conditions, 
with chiral crown ether 83 as the catalyst (Scheme 26). [3] 
 
Scheme 26. First successful enantioselective Michael addition under phase-
transfer condition. 
Another successful enantioselective Michael addition accomplished in the same study 
utilized a smaller chiral crown ether in the reaction of methyl 2-phenylproprionate 15 
with methyl acrylate 85 (Scheme 27). [3] 
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Scheme 27. Chiral crown ether catalyzed Michael addition. 
In 1989 Kenji Koga and co-workers were inspired by Cram’s results and decided to 
investigate chiral crown ethers. By varying the position, length and electronic effect of 
the chirality administering group, they hoped to acquire more information about the 
chiral recognition (Figure 6). [38] 
 
Figure 6. The chiral catalysts of Koga and co-workers. 
Crystal structures of catalysts 88 and 89 indicate that the potassium cations are 
located in the center of the crown structure and that the vicinal methyl groups are anti 
to each other and diaxial-like. The results from the study suggested that to be effective 
the methyl groups must be vicinal and diaxial-like in the crown potassium enolate 
complex. The best results were obtained with catalyst 88a (Scheme 30). [38] 
 
Scheme 28. Best results acquired by Koga and co-workers. 
 23 
 
Other chiral crown ethers used for this type of reaction are catalysts 89c, 93 and 94 
(Scheme 29). [2] 
 
Scheme 29. Other crown ethers that have been applied in phase-transfer catalysis. 
In 1986, Conn and co-workers, a research group at Merck decided to stereoselectively 
functionalize 2-alkylindanones using their original catalyst 22a (Scheme 30). [39] 
 
Scheme 30. Michael addition of Conn and co-workers. 
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Cinchona alkaloid derived catalysts have further been applied in this field. For 
example Vandewalle and co-workers decided in 1990 that they wanted to do 
extensive research on the subject of asymmetric alkylation of α-aryl substituted 
carbonyl compounds by means of chiral phase-transfer catalysts. With a few target 
molecules in mind they chose 3 tetralones, 2 non-fused α-arylketones, a lactone and 
an acyclic ketone for their study on asymmetric alkylation of α-aryl substituted 
carbonyl compounds. The best result in the category of non-fused substrates is shown 
in Scheme 31. [40] 
 
Scheme 31. Robinson annulation of 2-phenylcyclohexanone with methyl vinyl 
ketone. 
Encouraged by the results they decided to attempt the total synthesis of (+)-podocarp-
8(14)-en-13-one. One of the steps contained the asymmetric Michael addition of a 
tetralone derivative to an enone, followed by a one-pot Robinson annulation (Scheme 
32). [40] 
 
Scheme 32. Total synthesis of (+)-podocarp-8(14)-en-13-one. 
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In 1994 Shishido and co-workers were able to use the same route in their total 
synthesis of (+)-triptoquinone (Scheme 33). The only difference being that they used 
N-(p-trifluoromethyl)benzylcinchonidinium bromide 22b as their chiral catalyst instead 
of the N-(p-trifluoromethyl)benzyldehydrocinchonidinium bromide 99b used in the 
Vandewalle route.[41] 
 
Scheme 33. Total synthesis of (+)-triptoquinone. 
By utilizing N-(methylanthracenyl)quinidinium and -quininium chloride and solvent 
free conditions Plaquevent and co-workers hoped to be able to synthesize (-)-methyl 
dihydrojasmonate. This route enabled a short enantioselective synthesis of both 
enantiomers of methyl dihydrojasmonate (Scheme 34). [42] 
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Scheme 34. The solvent free Michael addition of Plaquevent and co-workers. 
It is noteworthy that in most reports catalysts based on cinchonine usually give a lower 
enantioselectivity than catalysts based on cinchonidine. 
Various functionalized α-alkyl amino acids have also been synthesized by 
enantioselective Michael addition of glycine derivatives. In 1998 Corey and co-
workers added a glycinate Schiff base to α,β-unsaturated carbonyl substrates. In 2000 
they used acrylonitrile as an acceptor, thus enabling the synthesis of (S)-ornithine as 
its dihydrochloride (Scheme 35). [11,43] 
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Scheme 35. Enantioselective Michael addition of glycine derivatives. 
O’Donnell and co-workers substituted the base in the reaction above against organic-
soluble, non-ionic bases BEMP and BTPP in 2001. In general, the less basic BEMP 
provided better results and tolerated several representative Michael acceptors. The 
group had been working on unnatural peptide synthesis since 1995, utilizing resin-
bound Schiff base esters for the solid phase synthesis of unnatural amino acids and 
peptides. Their method utilizing BEMP and BTPP was also applied to the solid-phase 
peptide synthesis (Scheme 36). [44] 
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Scheme 36. Organo-soluble BEMP as base in Michael addition. 
The chiral spiroammonium salts of Maruoka mentioned in Chapter 2 have also been 
used in asymmetric Michael additions. In 2005 Maruoka and co-workers decided to 
evaluate their spiroammonium salts in the Michael addition reactions of diethyl 
malonate and various chalcone derivatives. They also substituted the ester 
substituents of the malonate to study the steric effect on the enantioselectivity. By 
varying the electron donating/ withdrawing groups they were able to study the effect 
on the enantioselectivity. Lastly they exchanged the dialkyl malonates against 
malononitrile (Scheme 37). [45] 
 
Scheme 37. Chiral spiroammonium salt catalyzed Michael reaction of chalcones. 
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Maruoka and co-workers’ original spiroammonium salt was utilized in the total 
synthesis of (2S)-α-(hydroxymethyl) glutamate acid by Jew, Park and co-workers 
(Scheme 38). [46] 
 
Scheme 38. Total synthesis of (2S)-α-(hydroxymethyl) glutamate acid. 
Maruoka and co-workers wanted to create a method that would provide access to a 
variety of optically active γ-amino acid derivatives. Using their N-spiro C2-symmetric 
chiral quaternary ammonium bromide catalyst they succeeded in the conjugate 
addition of nitro alkanes to alkylidenemalonates (Scheme 39). [47] 
 
Scheme 39. Michael addition of nitropropane to an alkylidenemalonate. 
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Other interesting phase-transfer catalysts used in asymmetric Michael additions are 
for example Arai, Tsuji, and Nishida’s tartrate derived spiro compound (Scheme 40) 
[48]. 
 
Scheme 40.  Tartrate-derived N-spiroammonium salt catalyzed Michael addition. 
The two-center tartrate catalyst developed by Shibasaki and co-workers mentioned 
in chapter 2.2 was also utilized in a Michael addition (Scheme 41). [34] 
 
Scheme 41. Two-center tartrate catalyzed Michael addition. 
In 2003 Akiyama and co-workers decided to renew the “traditional” crown ether 
starting the catalyst synthesis from L-quebrachitol, an optically active chiro-inositol 
obtained from the exudate of rubber trees (Scheme 42) [49]. 
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Scheme 42. Chiro-inositol-derived crown ether catalyzed Michael addition. 
As a continuation on their work with bicyclic guanidines as chiral Brønsted base 
catalysts, Tan and co-workers decided to try and create structures more basic than 
guanidines. Pentanidine, a structure with five nitrogen atoms in conjugation was 
hypothesized to be more basic. The alkylated salt proved to work as a phase-transfer 
catalyst. Scheme 43 shows an example of the results comparable to the previous 
examples in this literary review. [50] 
 
Scheme 43. Pentanidium chloride catalyzed Michael addition. 
In 2013, Ooi and co-workers also decided to attempt an asymmetric Michael addition 
of electron-deficient triple bonds to azlactones with the help of closely related p-spiro 
chiral iminophosphorane catalysts mentioned in Chapter 2 (Scheme 44). [51] 
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Scheme 44. Michael addition of electron-deficient triple bonds to azlactones. 
Catalytic asymmetric Michael addition to electron-deficient triple bonds such as ynals, 
ynones and ynoates can be very challenging since they require geometric control of 
the newly formed olefin. The Ooi group proposed that the difference in the protonation 
pathway which is dependent on the proton donors, the conjugate acids of the catalysts 
as well as the properties of the electrophile, causes a complete switch of E/Z-
selectivity. Their results indicated that protonation followed the O-protonation pathway 
rather than the common C-protonation pathway. In order to confirm this, they 
employed cyanoacetylene as a new Michael acceptor (Scheme 45). Due to the 
carbanionic character of the intermediate α-cyano vinylic anion generated through the 
addition of a nucleophile, the contribution of the N-protonation pathway is expected to 
be negligible. Thus the direction of the proton transfer to the anionic carbon should 
be directly reflected in the E/Z-selectivity of the Michael adduct. [51] 
 
Scheme 45. Michael addition of an electron-deficient triple bond to a 
cyanoacetylene. 
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Ooi and co-workers continued their work with catalyst 141, using it for the 
enantioselective formal α-allylation of nitroalkanes through a catalyzed Michael 
reaction-Julia-Kocienski olefination sequence (Scheme 46). [52] 
 
Scheme 46. One-pot operation of chiral iminophosphorane catalyzed Michael 
reaction-Julia-Kocienski olefination sequence (PT = 1-phenyl-1H-tetrazol-5-yl). 
4. Results and discussion 
The aim of this study was to develop a method by which new stereocenters could be 
generated via chiral phase-transfer catalysis. The compounds could then be 
transformed for example to heterocycles (Scheme 47). 
 
Scheme 47. The aim of the thesis. 
M. Julia and co-workers utilized this route, including the Michael addition, to 
synthesize a number of racemic 3-aryl-piperidines in 1968 (Scheme 48). [53] 
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Scheme 48. Julia and co-workers’ route to 3-aryl-piperidines. 
They thus created for instance the following 3-aryl-piperidines (Figure 8). 
 
Figure 7. Racemic 3-aryl piperidines of Julia and co-workers. 
Evans and Turnbull published an article in May this year with a similar process in mind 
as M. Julia and co-workers, only utilizing another mechanism (Scheme 49). [54] 
 
Scheme 49. Rhodium-catalyzed allylic substitution with a nitrile anion. 
The first chiral phase-transfer catalyzed alkylation utilizing a similar starting material 
was first executed in 1980 by S. Juliá and co-workers. They used a chiral quaternary 
 35 
 
ammonium salt derived from ephedrine and a quinidinium salt to provide the 
enantioselectivity for the reaction (Scheme 50). With the ephedrine salt 153 they 
succeeded in obtaining an enantioselectivity of 0.7%. [55] 
 
Scheme 50. The first chirally catalyzed alkylation of α-ethylbenzyl cyanide. 
4.1. Starting point 
Expecting the route of Julia and co-workers to be possible to execute in an 
enantioselective manner by using a phase-transfer catalyst commercially available or 
synthesizable from literature, three main catalyst categories were chosen for further 
evaluation. The first category was the well-studied and much utilized Cinchona 
alkaloid, the second category was the chiral tetraminophosphonium salts created by 
Ooi and co-workers and the last category was the pentanidium salts created by Tan 
and co-workers. The C2-symmetric chiral quaternary ammonium salts of Maruoka and 
co-workers aroused interest, but unfortunately the synthesis of the catalysts 
developed by Maruoka and co-workers were far too laborious and time consuming for 
this thesis.  
Previous unpublished results from this laboratory indicated that ethyl phenylacetate 
was prone to double addition, so a decision was made to begin the optimization of the 
reaction with an α-substituted reactant. Hoping that methyl 2-phenylpropanoate 15 
used in the chiral phase-transfer catalysis by Cram and Sogah (Scheme 27) would 
give a little more steric bulk than an α-methylbenzyl cyanide it was synthesized from 
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2-phenylpropanoic acid, using dimethyl carbonate and 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) (Scheme 51). 
 
Scheme 51. Esterification of 2-phenylpropanoic acid. 
Ethyl 2-phenylpropanoate as well as isopropyl 2-phenylpropanoate were synthesized 
in the hope that they would either be more stable towards ester hydrolysis or sterically 
more hindered and thus give a better enantioselectivity than the methyl ester (Scheme 
52). 
 
Scheme 52. Esterification of 2-phenylpropanoic acid. 
As can be seen from the Bordwell table in chapter 2, the pKa of our ester is expected 
to be between 18 and 25, which means that the reaction may follow the interfacial 
mechanism (Figure 8).  
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Figure 8. The expected mechanism for Michael addition of methyl 2-phenyl-
propanoate to acrylonitrile. 
4.2. Optimization  
Once the starting material was available, the reaction conditions were sought after, 
and the synthesis of the racemate was attempted so that an enantioselectivity method 
could be established. Benzyltriethylammionium chloride (BTEA) was used as the 
catalyst in the synthesis of the racemate (Table 2). 
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Table 2. Michael addition of methyl 2-phenylpropanoate to acrylonitrilea. 
 
Base  
Catalyst 
amount 
Solvent t [h] Yield [%] 
KOtBu 0.05 eq 5 mol-% CH2Cl2 25 - 
KOtBu 0.05 eq 5 mol-% Toluene 18 b 
CsCO3 0.2 eq 10 mol-% CH2Cl2 1 - 
CsCO3 0.2 eq 10 mol-% Toluene 1 - 
NaOH (50%) 0.8+0.8 eq 10 mol-% CH2Cl2 1+3.5 22 
a Unless otherwise noted, the reaction was performed with 1.2 mmol of methyl 2-
phenylpropanoate, 1.3 mmol of acrylonitrile and the above mentioned amount of base 
and catalyst in solvent (2 ml) at 20°C. b Small conversion, but product was lost due to 
purification issues. 
Since the yield was minimal for the Michael addition of methyl 2-phenylpropanoate 15 
to acrylonitrile 114, we decided to investigate the Michael addition of α-methylbenzyl 
cyanide 17 to ethyl acrylate 124 (Scheme 53).  
 
Scheme 53. Michael addition to phenylpropanenitrile. 
This reaction was much faster and gave a better yield than the Michael addition of 
methyl 2-phenylpropanoate 15 to acrylonitrile 114. According to the Bordwell’s pKa 
table in chapter 2 the difference between the pKa of methyl 2-phenylpropanoate and 
α-methylbenzyl cyanide is small, but vital for this reaction to proceed as wished. Now 
that the starting material had been established the next step was making sure the 
background reactions would not overtake the catalyzed reaction. Not being sure 
which solvent was the optimal solvent, the background reaction rate was measured 
for both toluene (Figure 9) and dichloromethane (Figure 11) using UPLC-MS analysis. 
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Figure 9. Background reaction rate in toluene over several hours using different 
bases. 
Even with a large amount of 50% aqueous sodium hydroxide over several days at 
room temperature the background reaction would not interfere with the catalyzed 
reaction (Figure 10). 
 
Figure 10. Background reaction rate in toluene over several days using a large 
amount of sodium hydroxide. 
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Figure 11. Background reaction rate in dichloromethane over several hours using 
different bases. 
There were some concerns for autocatalysis due to the observation of a minimal 
amount of double addition of the intermediate enolate (Figure 12). The background 
reaction rates do not rule out autocatalysis, but they do not suggest autocatalysis 
either. 
 
Figure 12. Double addition of the intermediate enolate. 
The background reaction rate for potassium tert-butoxide was very high, and therefore 
potassium tert-butoxide could not be used as the base in the reaction. With enough 
cooling of the reaction mixture caesium hydroxide might be used and would be a good 
alternative at temperatures below the freezing point for aqueous base solutions. 
However, at room temperature, only caesium carbonate and aqueous sodium 
hydroxide would have an acceptable rate of background reactions (Scheme 54).  
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Scheme 54. N-benzylcinchonidinium bromide catalyzed Michael addition. 
The results from the reactions above indicated that the basicity of caesium carbonate 
was not adequate for the reaction. When the same reaction was repeated using 1 
equivalent of sodium hydroxide, but a small amount of distilled water was added to 
the reaction as well, thus lowering the concentration of the base, only a minimal 
conversion could be detected regardless of which solvent was used. The same effect 
could be detected when 30% aqueous potassium hydroxide was used (Scheme 55). 
Thus the conclusion that the concentration of the base used in the reaction was a vital 
part of Michael addition could be made. 
 
Scheme 55. Michael addition using potassium hydroxide as base. 
Another observation made when the reaction was repeated using N-(9-anthracenyl-
methyl)cinchonidinium chloride was that a large amount of base seems to hinder the 
reaction as well (Scheme 56). 
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Scheme 56. N-(9-anthracenylmethyl)cinchonidinium chloride catalyzed Michael 
addition. 
When the concentration and the quantity limitations of the base were taken into 
account, the reaction conditions were adjusted to the following (Scheme 57): 
 
Scheme 57. Adjusted reaction conditions. 
However, no increase in the enantioselectivity could be observed when the 
temperature was dropped from 20°C to 0°C (Scheme 57). Now that the amount and 
concentration of the base had been adjusted to the optimal conditions, the next step 
was to choose the optimal catalyst and the optimal amount of catalyst. Since many 
Cinchona derived catalysts were commercially available and there was plenty of 
literature available about many, it was decided that the project would begin with an 
evaluation of a few of these. There are four main structures to choose from; 
cinchonidine which is enantio-complementary with cinchonine and quinine which is 
enantio-complementary with quinidine (Figure 13). 
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Figure 13. Cinchona alkaloid structures. 
Denmark and Weintraub studied the catalyst structure-activity/selectivity relationships 
for Cinchona alkaloid-based asymmetric phase-transfer catalysis in 2011, and for 
their study they also created epi-cinchonidine, which could then be benzylated to the 
corresponding N-benzyl-epi-cinchonidinium bromide. [56] The epi-cinchonidine was 
included in our comparison between the main structures of the Cinchona alkaloids 
(Table 3).  
  
 44 
 
Table 3. Comparison between the main Cinchona alkaloid structures. 
 
a Unless otherwise noted, the reaction was performed with 1.5 mmol of α-
methylbenzyl cyanide, 2.0 mmol ethyl acrylate (1.3 eq), 1.5 mmol of 50% aqueous 
sodium hydroxide and 5 mol-% of catalyst in solvent (5 ml) at 0°C. 
There seemed to be no significant difference between using dichloromethane and 
toluene for the reaction, so toluene was used as default in the following reactions in 
this thesis. Only in the case when the catalyst was insoluble in chloroform was 
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dichloromethane used for the reaction since it seemed to dissolve at least a small 
amount of the catalyst.  
The results indicated that the optimal structure for further investigation would be 
cinchonidine or epi-cinchonidine, but since epi-cinchonidine is synthesized from 
cinchonidine and it did not give a better result than cinchonidine, it was decided that 
further investigation would be conducted using modified cinchonidine compounds 
only. It seems like the stereochemistry of C(9) does not play as a significant role as 
the rotation of the substituents at C(8) and other stereocenters at the quinuclidine 
group (Figure 14). The results obtained later in the project would be compared to the 
results obtained with the use of catalyst 24b. 
 
Figure 14. Numbering of carbons. 
The chemical subunits that are thought to have an impact on the catalytical abilities 
of the Cinchona alkaloids are the quinoline, the secondary alcohol, the terminal alkene 
and the sterically hindered tertiary amine. The easily modified parts of the Cinchona 
alkaloid are the secondary alcohol and the tertiary amine (Figure 15). 
 
Figure 15. The easily modified parts of the Cinchona alkaloids. 
Many have found that when allylated the Cinchona alkaloid derived catalyst may 
provide higher optical purities than when not. [11,16] Thus, the first alteration to our 
N-benzylcinchonidinium bromide 24b was to allylate the secondary alcohol (Scheme 
58). 
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Scheme 58. O-allyl-N-benzylcinchonidinium bromide catalyzed Michael addition. 
Unfortunately, the product was practically racemic when allowing for margin of error. 
Therefore, the only easily modified part left was the aryl attached to the tertiary amine. 
First the steric effects in ortho, meta and para positions of the aryl ring were 
investigated (Table 4). 
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Table 4. Comparison between sterically hindered cinchonidine compounds.a 
 
a Unless otherwise noted, the reaction was performed with 1.5 mmol of α-
methylbenzyl cyanide, 2.0 mmol ethyl acrylate (1.3 eq), 1.5 mmol of 50% aqueous 
sodium hydroxide and 5 mol-% of catalyst in toluene (5 ml) at 0°C. b Dichloromethane 
used as solvent 
Only catalyst 164b and 165b gave as good or minimally better enantioselectivities 
than catalyst 24b. This means that all other substitutions lowered the 
enantioselectivity achieved by the catalyst. However, it is difficult to draw conclusions, 
since the difference is quite minimal between the catalysts. Catalyst 27b gave a 
completely racemic product, meaning that big blades positioned sideways blocks the 
enantioselectivity providing part(s) of the catalyst. Catalyst 166b only altered the 
enantioselectivity minimally, meaning that expanding the blade in that position has 
almost no impact on the reaction. Catalyst 167b lowered the enantioselectivity 
substantially, suggesting that bulky substitutes at the para-position hinder the active 
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site(s) at the catalyst, while if the substitute is shifted to the meta-position (catalyst 
163b) it does not hinder the enantioselectivity as much. Since steric bulk did not aid 
the catalyst, the next area of interest was the electronic effect that could be provided 
by using fluorinated aryls, a nitro aryl or a nitrile aryl (Table 5). 
Table 5. Comparison between electronically influenced cinchonidine 
compounds.a 
 
a Unless otherwise noted, the reaction was performed with 1.5 mmol of α-
methylbenzyl cyanide, 2.0 mmol ethyl acrylate (1.3 eq), 1.5 mmol of 50% aqueous 
sodium hydroxide and 5 mol-% of catalyst in toluene (5 ml) at 0°C. b  Dichloromethane 
used as solvent 
Interestingly enough, when a trifluoromethyl group is added to the benzyl substituent, 
it gives an enantiomeric excess of the other enantiomer compared to a similar catalyst 
with a carbon substitution in the same position, like catalyst 165b and 167b. But unlike 
in the report by Jew and co-workers, the addition of fluoro substituents did not 
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dramatically increase the enantioselectivity [17]. The nitrile substituted catalyst 
(catalyst 170b) did minimally increase the enantioselectivity of the product and it was 
hoped that a more electronegative substituent at the meta-position might increase the 
enantioselectivity even further. Unfortunately no support for this hypothesis could be 
provided since the nitro substituted catalyst (catalyst 171b) deteriorated almost 
instantly when added to the reaction.  
The last Cinchona alkaloid-derived catalysts evaluated in the experimental part of this 
thesis were the dimeric Cinchona catalysts of Jew and co-workers [15]. Two dimeric 
cinchonidinium salts were prepared, related to those of Jew and co-workers, but 
unallylated since the O-allylated N-benzylcinchonidinium bromide 29b provided us 
with a racemic product (Table 6). 
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Table 6. Comparison between dimeric Cinchona alkaloid derived catalysts.a 
 
a Unless otherwise noted, the reaction was performed with 1.5 mmol of α-
methylbenzyl cyanide, 2.0 mmol ethyl acrylate (1.3 eq), 1.5 mmol of 50% aqueous 
sodium hydroxide and 5 mol-% of catalyst in dichloromethane (5 ml) at 0°C (reaction 
time 17 h). 
Since the para-substituted catalyst 167b decreased the enantioselectivity, it was not 
surprising that the para-dimeric catalyst 173 did not give rise to a more optically pure 
product. However, it was somewhat surprising that the meta-dimeric catalyst 172 
increased the enantioselectivity in such a manner as it did when the result of catalyst 
163b is considered. It would have been interesting to study the effect of a 2-
fluorosubstituted dimeric Cinchona catalyst on the reaction, but considering the yield 
and low enantioselectivity of the reaction catalyzed by catalyst 172, it is unlikely that 
it would have provided a completely optically pure product.  
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The partition coefficients (LogP) were calculated and the distribution coefficient was 
measured (LogD) for some of the Cinchona alkaloid derived catalysts (Table 7). The 
distribution coefficients were measured at pH 7.4, which is the physiological pH of 
blood serum, and therefore the standard value at which the distribution coefficient is 
measured at this institution. Since the reaction is performed in a more basic solution, 
a logD measurement at pH 10-12 might have given a more realistic correlation to the 
enantioselectivity. The log D value for N-benzyldihydroquinidinium bromide (Figure 
16) is comparable to that of the corresponding cinchonidine even though it lacks the 
vinyl and has a methoxy group on the quinoline. The methoxy group will make 
quinidine slightly more hydrophilic than the corresponding cinchonidine. 
 
Figure 16. LogD and logP values for N-benzyldehydroquinidinium bromide. 
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Table 7. The measured and calculated logD value for some of the catalysts. 
 
aDimeric Cinchona alkaloid derived catalysts 172 and 173 
Interestingly a correlation between the enantioselectivity of the catalyst and the 
distribution of the catalyst between phases at pH 7.4 can be observed (Figure 17). To 
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be kept in mind is that the enantioselective is not solely dependent on the distribution 
between phases but that steric and electronic effects play a significant role in the 
matter. The dimeric catalysts cannot be compared to the other catalysts, but it seems 
that the more hydrophilic a compound is the more enantioselective it is. Based on the 
logD value for the m-nitrobenzyl catalyst 170b, it would not have been more 
enantioselective than the m-cyanobenzyl, but because of the electronic effect 
provided by the electron withdrawing group, the nitrobenzyl might have provided for 
a better enantioselectivity. 
 
Figure 17. Correlation between LogD and the enantioselectivity at pH 7.4. 
Satisfied that the Cinchona alkaloid derived catalysts had been investigated as far as 
this thesis would allow, the next category, namely the chiral tetraaminophosphonium 
salts of Ooi and co-workers were studied (Table 8).  
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Table 8. Comparison of chiral tetraaminophosphonium chloride catalyzed 
Michael addition. 
  
a Reaction stalled after 2h, 1 eq of NaOH was added but no change could be detected. 
b Unless otherwise noted, the reaction was performed with 1.5 mmol of α-
methylbenzyl cyanide, 2.0 mmol ethyl acrylate (1.3 eq) and 1.5 mmol of 50% aqueous 
sodium hydroxide and 2 mol-% of catalyst in toluene (5 ml) at 20°C. 
The chiral tetraaminophosphonium salts developed by Ooi and co-workers did not 
catalyze in an enantioselective way, so further investigation in this area was deemed 
unnecessary. Guanidines are not basic enough structures for the reaction aimed at in 
this thesis, so instead it was decided that the pentanidium salt created by Tan and co-
workers would be investigated (Scheme 59). 
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Scheme 59. Pentanidium chloride catalyzed Michael addition. 
Unfortunately the pentanidium catalyst also gave a racemic product so further 
evaluation of this category was also deemed unnecessary.  
4.3.  Attempting to improve the enantioselectivity 
Accepting that the best results in this thesis were obtained with cinchonidine salts, we 
attempted to improve the enantioselectivity by lowering the reaction temperature to –
13°C (as low as the overnight equipment would allow). Since the theoretical freezing 
point for 50% aqueous sodium hydroxide is about 12°C and for 50% aqueous 
potassium hydroxide about 5°C, it would have been convenient to change the base 
used. However, when the potassium hydroxide was used the full conversion usually 
observed with sodium hydroxide did not occur, instead the conversion never reached 
above 70% (approximation based on UPLC-MS measuring, 210 nm) (Scheme 60). 
 
Scheme 60. Potassium hydroxide used as base in the Michael addition. 
As earlier mentioned caesium hydroxide in its solid form was a valid option as long as 
the reaction mixture was cold enough. Therefore, in the next experiment, caesium 
hydroxide was used (Scheme 61). As expected the sodium hydroxide in the parallel 
experiment was made inactive by being frozen. Unfortunately the temperature change 
did not improve the enantioselectivity. 
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Scheme 61. Michael addition at -13°C. 
Another attempt to increase the enantioselectivity was made by increasing the steric 
bulk of the benzyl cyanide. This was done by replacing the methyl group in 17 with an 
isopropyl group (Scheme 62).The enantioselectivity was increased slightly, from 22% 
ee to 30% ee for the corresponding reaction. 
 
Scheme 62. Michael addition of α-isopropylbenzyl cyanide to ethyl acrylate. 
4.4.  Other phase-transfer catalyzed Michael additions 
Now when the optimal reaction conditions were known, a return to the original concept 
was attempted only this time using methyl ester, ethyl ester and propyl ester. No 
reaction could be observed for the methyl ester 15 (Scheme 63). 
 
Scheme 63. Michael addition of methyl 2-phenylpropanoate to acrylonitrile. 
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The Michael addition of ethyl 2-phenylpropanoate to acrylonitrile was attempted both 
in room temperature and at 0°C (Scheme 64).  
 
Scheme 64. Michael addition of ethyl 2-phenylpropanoate to acrylonitrile. 
A small conversion (UPLC-MS based estimation) for the propyl ester could be 
observed, but it was not substantial enough for us to attempt to isolate the product 
(Scheme 65). 
 
Scheme 65. Michael addition of isopropyl 2-phenylpropanoate to acrylonitrile. 
A version of the Cram and Sogah reaction (Scheme 27) using the N-
benzylcinchonidinium bromide 24b as catalyst instead of chiral crown ethers. The 
methyl 2-phenylpropanoate was substituted for ethyl 2-phenylacetate and methyl 
acrylate was substituted for ethyl acrylate, in the hopes that they could withstand 
possible hydrolysis a bit better than the corresponding methyl esters. The conversion 
(UPLC-MS based estimation) reached 55%, but in the isolation most of the product 
must have been lost, since the acquired yield was only 7% (Scheme 66). This is 
believed to have occurred due to hydrolysis. 
 58 
 
 
Scheme 66. Synthesis of diethyl 2-phenylpentanedioate. 
The following reactions were also attempted but for the first reaction the results were 
inconclusive, while for the second one, it seems that the ethyl bromoacetate reacts 
with the catalyst, thus lessening the available amount of reagent for the reaction as 
well as altering the catalyst (Scheme 67).  
 
Scheme 67. Alkylation using chiral phase-transfer catalysts. 
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4.5. Conclusions 
Since the era of chiral crown ethers a large number of naturally occurring alkaloid 
derivatives have been elaborated as powerful and readily available chiral phase-
transfer catalysts as well as a large number of purely synthetic chiral quaternary 
onium salts have been developed. Three categories of phase-transfer catalysts were 
chosen for evaluation; unfortunately none of the catalysts evaluated in this thesis 
provided an enantioselectivity comparable to chiral crown ethers for the Michael 
additions aimed at in this thesis. The optimal reaction conditions were successfully 
created for the Michael addition of α-methylbenzyl cyanide to ethyl acrylate, but a 
catalyst which could provide for satisfactory enantioselectivity was not found for this 
reaction. 
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5. Experimental 
5.1. Experimental procedures 
Solvents and commercial reagents were purchased from commercial sources and 
used without purification. 1H and 13C NMR spectra were recorded on a Bruker Avance 
400 MHz spectrometer and chemical shifts are reported in ppm. LC-MS reaction 
monitoring data were recorded on a combination of Waters Acquity UPLC and Waters 
SQ mass detector, using a gradient of MeCN / HCO2H (0.1%) as eluent. The 
enantiopurity was measured with an Agilent HPLC 1200, Agilent HPLC 1100 and an 
Acquity UPC2 SFC, examples of typical spectra are provided in Appendix 16 and 17. 
The HRMS was measured with a Waters Micromass Premier Q-TOF. The distribution 
coefficients were calculated using ACD/Percepta, and measured using the shake 
flask method. For purification of products normal phase flash column chromatography 
was performed on a Teledyne Isco CombiFlash Rf+ with RediSep Rf silica columns 
and eluent of choice.  
5.2. Synthesis of starting materials 
Methyl-2-phenylpropanoate 15 
 
In a 50 ml round-bottomed flask 2-phenylproprionic acid (2.66 ml, 19.48 mmol) was 
diluted with dimethyl carbonate (25 ml, 297 mmol, 14.85 eq). 1,8-
diazabicyclo(5,4,0)undec-7-ene (2.99 ml, 19.98 mmol, 1 eq) was added to the solution 
in a portion wise manner. The reaction mixture was refluxed until judged to be 
complete (approximately 10 h). The reaction mixture was cooled to room temperature 
and diluted with 20 ml of ethyl acetate and 20 ml of distilled water. The phases were 
separated and the organic phase was washed with distilled water (25 ml), 2 M 
hydrochloric acid aqueous solution (2 x 20 ml), saturated sodium hydrogen carbonate 
(2 x 20ml) and distilled water (3 x 25 ml). The organic phase was dried over sodium 
sulfate and solvents were evaporated. The crude product was purified by flash column 
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chromatography using heptane and ethyl acetate as eluents. The product attained 
was a colorless liquid (2.51 g, 76%). 
Methyl 2-propanoate was prepared according to the procedure reported by W.-C. 
Shieh and co-workers. [57] 
1H NMR (CDCl3, 400 MHz) δ ppm 7.37 - 7.21 (m, 5H), 3.72 (q, J = 7.2 Hz, 1H), 3.66 
(s, 3H), 1.50 (d, J = 7.2 Hz, 1H). 
The 1H NMR results corresponded to those reported in literature. [58] 
Ethyl 2-phenylpropanoate 156 
 
Ethanol (30 ml, 514 mmol, 25.7 eq) was cooled to about 0ºC in a 100 ml three-necked 
flask under a nitrogen atmosphere, equipped with a gas cleanser apparatus placed in 
an ice bath. Thionyl chloride (4.39 ml, 59.9 mmol, 3 eq) was added drop wise to the 
ethanol and the mixture was stirred for 30 minutes on the ice bath. 2-Phenylpropionic 
acid (2.73 ml, 19.98 mmol) was added to the mixture in a drop wise manner. The 
reaction mixture was refluxed at 95ºC until judged to be complete, which was 
approximately after 2.5 h of refluxation. The reaction mixture was cooled to room 
temperature and the solvents were evaporated. The remainder was dissolved in ethyl 
acetate and sodium hydrogen carbonate was added dropwise to the mixture until no 
further generation of gas could be detected. Phases were separated and the organic 
phase was washed with brine and dried over sodium sulfate. Solvents were 
evaporated and the crude product was purified by flash column chromatography using 
ethyl acetate and heptane (0-100%) as eluent. The purification afforded 2.46 g (69%) 
of very lightly yellow-tinted liquid. 
Ethyl 2-propanoate was prepared according to the procedure reported by J.-E. 
Bäckvall and co-workers with some minor variations. [59] 
1H NMR (CDCl3, 400 MHz) δ ppm 7.36 - 7.21 (m, 5H), 4.19 - 4.05 (m, 2H), 3.70 (q, J 
= 7.2 Hz, 1H), 1.52 - 1.48 (d, J = 7.2 Hz, 1H), 1.20 (t, J = 7.1 Hz, 1H). 
The 1H NMR results corresponded to those reported in literature. [60] 
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Isopropyl 2-phenylpropanoate 158 
 
In a 100 ml round-bottomed flask equipped with a magnetic stirring bar 1.52 g (10.99 
mmol, 150 mol%) of potassium carbonate was added to 40 ml of acetonitrile. To this 
heterogeneous mixture 1.00 ml (7.32 mmol, 100 mol%) of 2-phenylproprionic acid 
was added in a drop wise manner, followed by 0.88 ml (8.79 mmol, 120 mol%) of 2-
iodopropane. The reaction was stirred at room temperature for 4.5 hours. Since no 
significant progress could be detected, the round-bottomed flask was equipped with 
a reflux condenser and the reaction mixture was refluxed for 1.5 hours. The reaction 
mixture was stirred overnight at room temperature and because the reaction had not 
completed, 5 ml of acetonitrile was added to the reaction mixture and it was refluxed 
for 2 hours. The remaining iodopropane had evaporated during the reflux so, 0.35 ml 
(0.5 eq) was added so that the reaction could complete. The reaction mixture was 
refluxed for 2 hours more. The reaction was considered to have completed, so 
solvents were evaporated from the mixture and saturated sodium bicarbonate solution 
was added to the remainder. The resulting mixture was extracted twice with ethyl 
acetate. The combined organic phases were washed with brine and dried over sodium 
sulfate. Solvents were evaporated yielding a yellow oil (mcrude=1.39 g). The yellow 
crude product was dissolved in dichloromethane and evaporated onto silica. The 
crude product was purified by flash column chromatography using a 40 g silica column 
and methyl tert-butyl ether and heptane as eluent. Solvents were evaporated from the 
fractions containing the product to afford a colorless oil (1.26 g, 89%). 
1H NMR (CDCl3, 400 MHz) δ ppm 7.34 - 7.20 (m, 5H), 4.99 (spt, J = 6.3 Hz, 1H), 3.67 
(q, J = 7.2 Hz, 1H), 1.50 - 1.46 (m, 3H), 1.22 (d, J=6.3 Hz, 2H), 1.13 (d, J=6.3 Hz, 1H). 
The 1H NMR results corresponded to those reported in literature. [61] 
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Isopropyl cyanide 176 
 
To a 100 ml round-bottomed flask benzylcyanide (5 ml, 43.3 mmol, 100 mol%), 2-
bromopropane (4.5 ml, 47.9 mmol, 110 mol%) and tetrabutylammonium bromide 
(0.279g, 0.866 mmol, 2 mol%) was added. The mixture was stirred vigorously before 
the drop wise addition of 60% potassium hydroxide (20.25 g, 217 mmol, 500 mol%). 
The reaction was heated to 45 ºC and stirred vigorously until judged to be complete, 
approximately 5 h after initiation. The reaction mixture was cooled to room 
temperature and 10 ml of distilled water as well as 10 ml dichloromethane were added 
and the phases were separated. The organic phase was washed with 20 ml of distilled 
water. The combined aqueous phases were extracted with dichloromethane (2 x 20 
ml). The combined organic phases were washed with brine and dried over sodium 
sulfate. The crude product was purified by vacuum distillation, affording 176 (5.37 g, 
78 %). 
Isopropyl 2-propanoate was prepared according to the procedure reported by M. 
Fedoryński and co-workers. [62] 
1H NMR (CDCl3, 400 MHz) δ ppm 7.41 - 7.27 (m, 5H), 3.66 (d, J=6.3 Hz, 1H), 2.20 - 
2.07 (m, 1H), 1.08 - 1.01 (m, 6H) 
The 1H NMR results corresponded to those reported in literature. [63] 
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5.3. Products 
Ethyl 4-cyano-4-phenylvalerate 160 
 
To a suitable round-bottomed flask equipped with a magnetic stirring bar the catalyst 
of choice (2-5 mol-%) was added to the solvent of choice (0.3 M). The base (100 mol-
%) was added to the mixture under vigorous stirring. In the case of cooling, the 
reaction mixture was placed under a nitrogen atmosphere. α-Methylbenzyl cyanide 
17 (0.20 ml, 1.50 mmol, 100 mol-%) was added to the reaction mixture in a dropwise 
manner. The reaction mixture was stirred for 15 minutes before ethyl acrylate 124 
(0.21 ml, 1.95 mmol, 130 mol-%) was added to the reaction mixture. The reaction was 
monitored using UPLC-MS analysis and stirred until judged to be complete. The 
reaction mixture was subsequently quenched with brine and phases were separated. 
In the case of emulsions, the organic phase was washed twice more with brine and 
the combined aqueous phases were extracted once with dichloromethane. The 
combined organic phases were dried over Na2SO4 and solvents were evaporated. 
The crude product was purified by flash column chromatography using a suitable silica 
column and methyl tert-butyl ether and heptane (0-10%) as eluent.  
13C NMR (CDCl3, 400 MHz) δ ppm 172.3, 139.2, 129.2, 128.2, 125.6, 122.8, 60.8, 
42.1, 36.9, 30.7, 28.0, 14.3. 
1H NMR (CDCl3, 400 MHz) δ ppm 7.46-7.30 (m, 5H), 4.14-4.01 (m, 2H), 2.53-2.44 (m, 
2H), 2.36-2.25 (m, 2H), 2.24-2.15 (m, 1H), 1.75 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H). 
HRMS (Q-TOF): m/z calculated for C14H18NO2 [M+H] 232.1338, found: 232.1337. 
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Ethyl 4-cyano-5-methyl-4-phenylhexanoate 177 
 
The catalyst (0.08 mmol, 5 mol-%) was added to a suitable round-bottomed flask 
equipped with a magnetic stirring bar containing toluene (0.3 M). 50% aqueous 
sodium hydroxide (0.080 ml, 1.51 mmol, 100 mol-%) was added to the mixture under 
vigorous stirring. In the case of cooling, the reaction mixture was placed under a 
nitrogen atmosphere. α-Isopropylbenzyl cyanide 176 (0.24 g, 1.51 mmol, 100 mol-%) 
was added to the reaction mixture in a dropwise manner. The reaction mixture was 
stirred for 15 minutes before ethyl acrylate 124 (0.21 ml, 1.96 mmol, 130 mol-%) of 
was added to the reaction mixture. The reaction was monitored using UPLC-MS 
analysis and stirred until judged to be complete. The reaction mixture was 
subsequently quenched with brine and phases were separated. The organic phase 
was washed twice more with brine and the combined aqueous phases were extracted 
once with dichloromethane. The combined organic phases were dried over Na2SO4 
and solvents were evaporated. The crude product was purified by flash column 
chromatography using a suitable silica column and methyl tert-butyl ether and 
heptane (0-10%) as eluent. The product obtained was a colorless liquid. 
1H NMR (CDCl3, 400MHz) δ ppm 7.42 - 7.35 (m, 4H), 7.35 - 7.27 (m, 1H), 4.12 - 3.99 
(m, 2H), 2.55 - 2.33 (m, 2H), 2.24 - 2.10 (m, 2H), 2.00-1.89 (m, 1H), 1.27 - 1.17 (m, 
6H), 0.79 (d, J = 6.8 Hz, 3H). 
The 1H NMR results corresponded to those reported in literature. [64] 
Methyl 4-cyano-2-methyl-2-phenylbutanoate 159 
 
The catalyst of choice (5-10 mol-%) was added to the solvent of choice (0.6 M) in a 
suitable round-bottomed flask equipped with a magnetic stirring bar. The base of 
choice (5–80 mol-%) was added to the mixture under vigorous stirring. α-Methyl 2-
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phenylpropanoate 15 (0.20 g, 1.22 mmol, 100 mol-%) was added to the reaction 
mixture in a dropwise manner. The reaction mixture was stirred for 15 minutes before 
acrylonitrile 114 (0.09 ml, 1.34 mmol, 110 mol-%) was added to the reaction mixture. 
The reaction was monitored using UPLC-MS analysis and stirred until judged to be 
complete. The reaction mixture was subsequently quenched with brine and phases 
were separated. The aqueous phase was extracted thrice with dichloromethane. The 
combined organic phases were dried over Na2SO4 and solvents were evaporated. 
The crude product was purified by flash column chromatography using a suitable silica 
column and methyl tert-butyl ether and heptane (0–10%) as eluent. 
13C NMR (CDCl3, 400 MHz) δ ppm 175.6, 141.3, 129.0, 127.7, 125.9, 119.7, 52.6, 
49.8, 35.6, 22.4, 13.3. 
1H NMR (CDCl3, 400 MHz) δ ppm 7.39-7.21 (m, 5H), 3.70 (s, 3H), 2.38-2.13 (m, 4H), 
1.63 (s, 3H). 
HRMS (Q-TOF): m/z calculated for C13H16NO2 [M+H] 218.1181, found: 218.1180. 
Diethyl 2-phenylpentanedioate 181 
 
N-benzylcinchonidinium bromide 24b (0.02 g, 0.05 mmol, 5 mol-%) was added to 3 
ml of toluene in a 10 ml round-bottomed flask equipped with a magnetic stirring bar. 
50% aqueous sodium hydroxide (0.02 ml, 0.46 mmol, 50 mol-%) was added to the 
mixture under vigorous stirring followed by ethyl phenylacetate 12 (0.15 ml, 0.91 
mmol, 100 mol-%). The reaction mixture was stirred for 5 minutes before ethyl acrylate 
124 (0.10 ml, 0.91 mmol, 100 mol-%) was added to the reaction mixture. The reaction 
mixture was stirred for 3 h. UPLC-MS results indicated that the reaction had stopped, 
so 0.02 ml of 50% sodium hydroxide (0.46 mmol, 0.5 eq) was added to the reaction 
mixture. The reaction mixture was stirred for 69 h, but no significant progress could 
be detected. The reaction mixture was quenched with 5 ml of brine and phases were 
separated. The organic phase was washed with brine (3 x 5 ml), and the combined 
aqueous phases were extracted with dichloromethane. The combined organic phases 
were dried over Na2SO4 and solvents were evaporated. The crude product was 
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purified by flash column chromatography using a 4g silica column and methyl tert-
butyl ether and heptane (0-10%) as eluent. 0.02 g of colorless liquid was obtained in 
a yield of 6.92%. 
13C NMR (CDCl3, 400 MHz) δ ppm 173.6, 173.0, 138.5, 128.8, 128.1, 127.5, 61.0, 
60.5, 50.8, 32.1, 28.6, 14.3, 14.2. 
1H NMR (CDCl3, 400 MHz) δ ppm 7.35-7.23 (m, 5H), 4.20-4.04 (m, 4H), 3.60 (t, J = 
7.6 Hz, 1H), 2.42-2.31 (m, 1H), 2.29-2.22 (m, 2H), 2.17-2.06 (m, 1H), 1.22 (dt, J = 
14.7, 7.2 Hz, 6H). 
HRMS (Q-TOF): m/z calculated for C15H20O4Na [M+Na] 287.1259, found: 287.1259. 
5.4. Catalysts 
 
General Procedure I: To a flask equipped with a magnetic stirring bar and a reflux 
condenser the desired Cinchona alkaloid (cinchonidine, cinchonine, dehydroquinidine 
or epi-cinchonidine) (100 mol-%) was added, as well as dry THF (0.1 M), and the 
desired benzyl bromide or benzyl chloride derivative (100 mol-%). The mixture was 
heated to reflux until judged to be complete by LC-MS-analysis. The mixture was then 
cooled to room temperature and MTBE was added (twice the amount of THF). The 
resulting suspension was stirred for at least 1h and the precipitated solids were 
isolated by filtration. The product in question was dried in a vacuum oven at 40°C 
overnight. 
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General Procedure II: To a flask equipped with a magnetic stirring bar and a reflux 
condenser cinchonidine (100 mol-%) was added, as well as dry THF (0.1 M), and the 
desired benzyl bromide derivative (110 mol-%). The mixture was heated to reflux until 
judged to be complete by LC-MS-analysis. The mixture was then cooled to room 
temperature and MTBE was added (twice the amount of THF). The resulting 
suspension was stirred for at least 1h and the precipitated solids were isolated by 
filtration. The product in question was dried in a vacuum oven at 40 °C overnight. 
Epi-cinchonidine 
 
Epi-cinchonidine was prepared according to the procedure reported by Denmark and 
co-workers with some minor variations. [56] 
Cinchonidine (2.94 g, 10 mmol, 100 mol-%), triphenylphosphine (2.89 g, 11.00 mmol, 
110 mol-%) and 4-nitrobenzoic acid (5.18 g, 31.0 mmol, 310 mol-%) were dissolved 
in dry tetrahydrofuran (125 ml, 0.08 M) in a 250 ml three-necked round-bottomed flask 
under a nitrogen atmosphere. The resulting mixture was cooled in an ice-bath. 
Diisopropyl azodicarboxylate (2.2 ml, 11.17 mmol, 110 mol-%) was added to the 
mixture in a drop wise manner. The reaction mixture was stirred for one hour at 2-5ºC 
then allowed to warm to room temperature under the course of 1.5 h. The reaction 
mixture was diluted with methyl tert-butyl ether (50 ml) and extracted with 1 N 
hydrochloric acid aqueous solution (3 x 50 ml). The pH of the combined aqueous 
phases was raised using solid potassium carbonate to a pH of 9. The resulting 
solution was extracted with methyl tert-butyl ether (3 x 50 ml) then once using 
dichloromethane (50 ml). The combined organic extracts were dried over sodium 
sulfate and solvents were evaporated. The crude product was purified by flash column 
chromatography using methanol and dichloromethane (0-20%). The product was 
further purified by recrystallization from 2-propanol affording the product as an oil 
(1.34 g, 46%). 
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1H NMR (CDCl3, 400 MHz) δ ppm 8.77 (d, J = 4.5 Hz, 1H), 8.07 (dd, J = 0.9, 8.5 Hz, 
1H), 7.97 - 7.92 (m, 1H), 7.63 (ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 7.56 (d, J = 4.5 Hz, 1H), 
7.35 (ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 5.75 - 5.65 (m, 1H), 5.65 - 5.62 (m, 1H), 4.96 - 
4.87 (m, 2H), 4.56 (br s, 1H), 3.51-3.42 (m, 1H), 3.11 - 3.00 (m, 2H), 2.66 - 2.54 (m, 
2H), 2.28 - 2.20 (m, 1H), 1.82 - 1.69 (m, 3H), 1.55 - 1.42 (m, 2H). 
The 1H NMR results corresponded to those reported in literature. [56] 
N-benzyl-epi-cinchonidinium bromide 24c 
 
Following General Procedure I, epi-chinchonidine (0.40 g, 1.36 mmol) and benzyl 
bromide (0.16 ml, 1.36 mmol) gave the product as a white solid (reaction time 7 h). 
Isolated yield 93%.  
1H NMR (CDCl3, 400 MHz) δ = 8.81 (d, J = 4.5 Hz, 1H), 8.18 - 8.12 (m, 1H), 7.82 (d, 
J=4.5 Hz, 1H), 7.70 - 7.60 (m, 3H), 7.25 - 7.10 (m, 5H), 6.60 - 6.56 (m, 1H), 6.56-6.50 
(m, 1H), 5.95 (d, J = 11.9 Hz, 1H), 5.56 (d, J = 11.9 Hz, 1H), 5.46 - 5.35 (m, 1H), 5.33 
- 5.26 (m, 1H), 4.91 (dd, J = 10.4, 1.3 Hz, 1H), 4.69 - 4.58 (m, 1H), 4.18 - 4.09 (m, 
1H), 3.91 -3.83 (m, 1H), 3.16 – 3.06 (m, 2H), 2.47 (br s, 1H), 2.12 - 2.00 (m, 1H), 1.95 
- 1.79 (m, 2H), 1.64 - 1.52 (m, 1H), 1.08 - 0.98 (m, 1H). 
The 1H NMR results for this compound have been reported in literature. [56] 
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N-benzyldehydroquinidinium bromide 162a 
 
Following General Procedure I: hydroquinidine (0.20 g, 0.61 mmol) and 3-
phenylbenzyl bromide (0.073 ml, 0.61 mmol) gave the product as a lilac solid (reaction 
time 7.5 h). Isolated yield 100%. 
13C NMR (CDCl3, 400 MHz) δ ppm 158.0, 147.3, 144.1, 143.0, 134.0, 131.6, 130.3, 
129.1, 127.3, 126.2, 120.9, 120.7, 102.6, 68.1, 66.0, 62.8, 56.8, 56.2, 55.9, 36.1, 24.6, 
24.5, 24.3, 21.4, 11.5. 
1H NMR (CDCl3, 400 MHz) δ ppm 9.56 (d, J = 4.5 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 
7.74-7.69 (m, 3H), 7.42 (d, J =2.5, 1H), 7.39-7.28 (m, 3H), 7.20 (dd, J = 9.2, 2.6 Hz, 
1H), 6.64-6.60 (m, 1H), 6.48-6.43 (m, 1H), 5.62 (d, J = 12.1 Hz, 1H), 5.09 (d, J = 12.0 
Hz, 1H), 4.27-4.11 (m, 2H), 4.00-3.92 (m, 1H), 3.89(s, 3H), 3.42-3.31 (m, 1H), 2.90-
2.78 (m, 1H), 2.47-2.38 (m, 1H), 2.38-2.28 (m, 1H), 1.82-1.67 (m, 2H), 1.66-1.45 (m, 
4H), 0.98-0.89(m, 1H), 0.89-0.80 (m, 3H). 
HRMS (Q-TOF): m/z calculated for C27H33N2O2 [M]+ 417.2542, found: 417.2543. 
N-(3-phenyl)benzylcinchonidinium bromide 163b 
 
Following General Procedure II: cinchonidine (0.40 g, 1.36 mmol, 100 mol-%) and 3-
phenylbenzyl bromide (0.37 g, 1.50 mmol, 110 mol-%) gave the product as a slightly 
peach coloured solid (reaction time 6h). Isolated yield 95%. 
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13C NMR (DMSO, 400 MHz) δ ppm 150.2, 147.6, 145.2, 140.7, 139.3, 138.1, 132.7, 
132.0, 129.8, 129.5, 129.4, 129.0, 128.7, 128.3, 127.9, 127.3, 126.9, 124.3, 123.7, 
120.1, 116.4, 67.6, 64.0, 62.5, 59.3, 50.8, 36.9, 25.9, 24.3, 21.0. 
1H NMR (DMSO, 400 MHz) δ ppm 9.00 (d, J = 4.3 Hz, 1H), 8.37 (d, J = 8.3 Hz, 1H), 
8.15-8.07 (m, 2H), 7.91-7.63 (m, 9H), 7.55-7.47 (m, 2H), 7.46-7.39 (m, 1H), 6.78 (d, 
J = 4.5 Hz, 1H), 6.64-6.58 (m, 1H), 5.70 (ddd, J = 17.0, 10.3, 6.4 Hz, 1H), 5.36-5.27 
(m, 1H), 5.19 (d, J = 15.8 Hz, 2H), 4.95 (d, J = 10.5 Hz, 1H), 4.45-4.34 (m, 1H), 4.03-
3.94 (m, 1H), 3.92-3.82 (m, 1H), 3.49-3.28 (m, 4H), 2.72 (brs, 1H), 2.20-1.97 (m, 3H), 
1.91-1.76 (m, 1H), 1.40-1.28 (m, 1H). 
HRMS (Q-TOF): m/z calculated for C32H33N2O [M]+ 461.2593, found: 461.2608. 
N-(3,5-dimethyl)benzylcinchonidinium bromide 164b 
 
Following General Procedure I, cinchonidine (0.50 g, 1.70 mmol) and α-
bromoesitylene (0.34 g, 1.70 mmol) gave the product as a white solid (reaction time 
5h). Isolated yield 91%. 
13C NMR (CDCl3, 400 MHz) δ ppm 149.6, 147.3, 144.7, 138.2, 136.2, 131.6, 131.6 
129.6, 128.5, 127.4, 126.9, 123.8 123.2, 119.9, 117.8, 66.8, 65.2, 62.4, 60.2, 50.5, 
38.0, 26.6, 25.2, 22.5, 21.3. 
1H NMR (CDCl3, 400 MHz) δ ppm 8.80 (d, J = 4.5 Hz, 1H), 8.20-8.13 (m, 1H), 7.82 
(d, J = 4.4 Hz, 1H), 7.69-7.63 (m, 1H), 7.31-7.26 (m, 2H), 7.22-7.14 (m, 2H), 7.82 (s, 
1H), 6.62-6.57 (m, 1H), 6.52-6.56 (m, 1H), 5.90-5.83 (m, 1H), 5.47-5.36 (m, 2H), 5.33-
5.25 (m, 1H), 4.90 (dd, J = 10.4, 1.2 Hz, 1H), 4.66-4.56 (m, 1H), 4.17-4.08 (m, 1H), 
3.93-3.85 (m, 1H), 3.23-3.11 (m, 2H), 2.52-2.43 (m, 1H), 2.21 (s, 6H), 2.09-1.99 (m, 
1H), 1.92-1.80 (m, 2H), 1.63-1.53 (m, 1H), 1.06-0.96 (m, 1H).  
HRMS (Q-TOF): m/z calculated for C28H33N2O [M]+ 413.2593, found: 413.2598. 
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N-(2,4-dimethyl)benzylcinchonidinium chloride 165b 
 
Following General Procedure I, cinchonidine (0.50 g, 1.70 mmol) and 2,4-
dimethylbenzyl chloride (0.25 ml, 1.70 mmol) gave the product as a white solid 
(reaction time 25 h). Isolated yield 66%. 
13C NMR (CDCl3, 400 MHz) δ ppm 149.3, 146.9, 145.5, 140.3, 139.7, 136.0, 135.3, 
131.9 129.2, 128.2, 126.9, 126.6, 123.7 123.3, 123.2, 119.6, 117.7, 66.1, 65.9, 59.4, 
58.8, 49.6, 38.0, 26.3, 25.4, 22.8, 21.3, 21.08. 
1H NMR (CDCl3, 400 MHz) δ ppm 8.77 (d, J = 4.4 Hz, 1H), 8.29 (d, J = 8.3 Hz, 1H), 
7.85-7.79 (m, 2H), 7.58 (d, J = 5.8 Hz, 1H), 7.53 (d, J = 7.7 Hz, 1H) 7.07-6.99 (m, 1H), 
6.94-6.86 (m, 2H), 6.63 (s, 1H), 6.57-6.50 (m, 1H), 6.11 (d, J = 12.2 Hz, 1H), 5.50 (d, 
J = 12.3 Hz, 1H), 5.46-5.31 (m, 2H), 4.90-4.83 (m, 1H), 4.67-4.55 (m, 1H), 4.37-4.27 
(m, 1H), 4.18-4.10 (m, 1H), 3.07 (dd, J = 12.6, 10.6 Hz, 1H) 2.87-2.77 (m, 1H), 2.47-
2.38 (m, 1H), 2.32-2.27 (m, 6H), 2.03-1.93 (m, 1H), 1.84 (brs, 1H), 1.76-1.66 (m, 1H), 
1.57-1.45 (m, 1H), 0.94-0.81 (m, 1H). 
HRMS (Q-TOF): m/z calculated for C28H33N2O [M]+ 413.2593, found: 413.2603. 
N-(2-naphtylmethyl)cinchonidinium bromide 166b 
 
Following General Procedure I: cinchonidine (0.40 g, 1.36 mmol) and 2-
(bromomethyl)naphthalene (0.30 g, 1.36 mmol) gave the product as a slightly peach 
colored solid (reaction time 5 h). Isolated yield 92%. 
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1H NMR (CDCl3, 400 MHz) δ ppm 8.78 (d, J = 4.5 Hz, 1H), 8.19 - 8.10 (m, 1H), 7.77 
(d, J = 4.5 Hz, 1H), 7.64 - 7.47 (m, 2H), 7.10 - 7.01 (m, 1H), 7.01 - 6.96 (m, 2H), 6.48 
- 6.42 (m, 1H), 6.42 - 6.37 (m, 1H), 6.23 (d, J = 12.2 Hz, 1H), 5.61 (d, J = 12.1 Hz, 
1H), 5.45 - 5.31 (m, 1H), 4.96 - 4.84 (m, 1H), 4.67 - 4.56 (m, 1H), 4.28 - 4.17 (m, 1H), 
4.08 - 3.98 (m, 1H), 3.13 - 2.99 (m, 2H), 2.57 - 2.47 (m, 1H), 2.18 - 2.02 (m, 1H), 1.95 
(br s, 1H), 1.92 - 1.77 (m, 1H), 1.73 - 1.56 (m, 1H), 1.06 - 0.93 (m, 1H) 
1H NMR results for this compound have been reported in literature. [56] 
N-(4-isopropyl)benzylcinchonidinium bromide 167b 
 
Following General Procedure I, cinchonidine (0.50 g, 1.70 mmol) and 4-isopropyl 
benzyl bromide (0.30 mL, 1.76 mmol) gave the product as a pinkish solid (reaction 
time 4 h). Isolated yield 89%.  
13C NMR (CDCl3, 400 MHz) δ ppm 150.9, 149.8, 147.5, 144.7, 136.3, 134.1, 129.9, 
128.7, 127.5, 126.9, 124.4, 124.0, 123.2, 120.1, 117.9, 67.5, 64.8, 62.5, 60.4, 50.7, 
38.0, 33.8, 26.6, 25.1, 24.2, 23.5, 22.2. 
1H NMR (CDCl3, 400 MHz) δ ppm 8.82 (d, J = 4.5 Hz, 1H), 8.16-8.10 (m, 1H), 7.81 
(d, J = 4.5 Hz, 1H), 7.79-7.74 (m, 1H), 7.68 (d, J = 8.1 Hz, 2H), 7.33-7.25 (m, 2H), 
7.07 (d, J = 8.0 Hz, 2H), 6.60-6.52 (m, 2H), 5.73 (d, J = 12.0, 1H), 5.51 (d, J = 12.0 
Hz, 1H), 5.43 (ddd, J = 17.1, 10.5, 6.3 Hz, 1H), 5.25-5.17 (m, 1H), 4.91 (dd, J = 10.5, 
1.2 Hz, 1H) 4.67-4.57 (m, 1H), 4.08-4.00 (m, 1H), 3.81-3.72 (m, 1H), 3.27-3.11 (m, 
2H), 2.81 (dddd, app. nonet, J = 6.9 Hz, 1H), 2.50 (brs, 1H), 2.14-2.05 (m, 1H), 1.98-
1.88 (m, 2H), 1.67-1.56 (m, 1H), 1.24 (dd, J = 13.3 Hz, 6.9, 6H), 1.15-1.04 (m, 1H). 
HRMS (Q-TOF): m/z calculated for C29H35N2O [M]+ 427.2749, found: 427.2741. 
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N-(4-trifluoromethylbenzyl)cinchonidinium bromide 22b 
 
Following General Procedure I, cinchonidine (0.40 g, 1.36 mmol) and 4-
(trifluoromethyl)benzyl bromide (0.21 mL, 1.36 mmol) gave the product as a white 
solid (reaction time 4 h). Isolated yield 90%.  
13C NMR (CDCl3, 400 MHz) δ ppm 149.5, 147.1, 144.1, 135.7, 134.6, [132.8, 132.4, 
132.1, 131.8], 131.2, 129.7, 128.4, [127.5, 124.8, 122.1, 119.4], 127.3, [125.5, 125.4], 
123.3, 122.7, 119.7, 118.1, 67.2, 65.3, 60.9, 60.1, 50.6, 37.8, 26.3, 25.1, 22.6. 
1H NMR (CDCl3, 400 MHz) δ ppm 8.79 (d, J = 4.5 Hz, 1H), 8.19-8.14 (m, 1H), 7.88 ( 
d, J = 7.8 Hz, 2H), 7.79 (d, J = 4.4 Hz, 1H), 7.56-7.51 (m, 1H), 7.41 (d, J = 8.0 Hz, 
2H), 7.04-6.99 (m, 2H), 6.54 (d, J = 5.88 Hz, 1H), 6.50-6.46 (m, 1H), 6.36 (d, J = 11.9 
Hz, 1H), 5.55 (d, J = 11.9 Hz, 1H), 5.43-5.29 (m, 2H), 4.93-4.89 (m, 1H), 4.69-4.59 
(m, 1H), 4.27-4.19 (m, 1H), 4.04-3.97 (m, 1H), 3.07-2.90 (m, 2H), 2.52-2.45 (m, 1H), 
2.12-2.02 (m, 1H), 1.93 (brs, 1H), 1.88-1.79 (m, 1H), 1.66-1.55 (m, 1H), 1.04-0.94 (m, 
1H).  
Note: N-(4-trifluoromethylbenzyl)cinchonidinium bromide is a well-known and used 
compound, but no NMR data could be found [40].  
HRMS (Q-TOF): m/z calculated for C27H28F3N2O [M]+ 453.2161, found: 453.2154. 
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N-(4-chloro-[2-trifluoromethyl])benzylcinchonidinium bromide 168b 
 
Following General Procedure II: cinchonidine (0.40 g, 1.36 mmol, 100 mol-%) and 4-
chloro-2-(trifluoromethyl)benzyl bromide (0.407 g, 1.49 mmol, 110 mol-%) gave the 
product as a white solid (reaction time 7h). Isolated yield 88%. 
13C NMR (CDCl3, 400 MHz) δ ppm 150.2, 147.9, 144.5, 138.5, 137.9, 135.7, 133.2, 
[133.1, 132.8, 132.5, 132.2], 130.7, 129.2, [128.3, 128.3, 128.2, 128.2], 127.5, [127.4, 
124.6, 121.9, 119.2], 124.3, 123.7, 122.3, 120.3, 118.3, 71.5, 64.0, 61.2, 59.1, 52.1, 
38.0, 26.1, 25.1, 21.9. 
1H NMR (CDCl3, 400 MHz) δ ppm 8.93 (d, J = 4.5 Hz, 1H), 8.44 (d, J = 8.4Hz, 1H), 
8.09 (d, J = 8.3 Hz, 1H), 8.03 (d, J = 7.84 Hz, 1H), 7.87 (d, J = 4.4 Hz, 1H), 7.74 (d, J 
= 2.2 Hz, 1H), 7.68 (dd, J = 8.4, J = 2.1, 1H), 7.54 (dt, J = 44.5, 7.4 Hz, 2H), 6.78 (d, 
J = 6.1 Hz, 1H), 6.54-6.44 (m, 1H), 6.38 (d, J = 6.4 Hz, 1H), 5.52 (ddd, J = 17.0, 10.5, 
6.4 Hz, 1H), 5.36-5.24 (m, 1H), 5.17-5.08 (m, 2H), 5.01 (dd, J = 10.6, 1.2 Hz, 1H), 
3.96-3.86 (m, 1H), 3.46 (br, 1H), 3.25 (td, J = 11.5, 5.6Hz, 1H), 3.08 (dd, J = 12.5, 
10.5 Hz, 1H), 2.64-2.55 (m, 1H), 2.40-2.29 (m, 1H), 2.05-1.99 (m, 1H), 1.87-1.76 (m, 
1H, partially beneath THF), 1.37-1.26 (m, 1H).  
HRMS (Q-TOF): m/z calculated for C27H27ClF3N2O [M]+ 487.1764, found: 487.1774. 
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N-(3,4-difluorobenzyl)cinchonidinium bromide 169b 
 
Following General Procedure I, cinchonidine (0.50 g, 1.70 mmol) and 3,4-
difluorobenzyl bromide (0.22 mL, 1.70 mmol) gave the product as a beige solid 
(reaction time 5 h). Isolated yield 90%.  
13C NMR (CDCl3, 400 MHz) δ ppm [152.8, 152.7, 151.1, 150.9], [150.3, 150.2, 148.6, 
148.4] 149.4, 147.0, 144.1, 135.7, [131.2, 131.1, 131.1, 131.1] 129.6, 128.3, 127.2, 
[124.3, 124.2, 124.2], 123.3, [123.3, 123.1] 122.7, 119.6, 118.0, [117.7, 117.5], 66.8, 
65.3, 60.5, 59.8, 50.3, 37.8, 26.3, 25.2, 22.7. 
1H NMR (CDCl3, 400 MHz) δ ppm 8.78 (d, J = 4.5 Hz, 1H), 8.17-8.11 (m, 1H), 7.77 
(d, J = 4.4 Hz, 1H), 7.65-7.48 (m, 3H), 7.10-7.01 (m, 1H), 7.01-6.95 (m, 2H), 6.49-
6.6.41 (m, 1H), 6.42-6.37 (m, 1H), 6.23 (d, J = 12.1 Hz, 1H), 5.61 (d, J = 12.1 Hz, 1H), 
5.45-5.31 (m, 2H), 4.94-4.87 (m, 1H), 4.68-4.56 (m, 1H), 4.26-4.17 (m, 1H), 4.07-3.99 
(m, 1H), 3.13-2.99 (m, 2H), 2.56-2.47 (m, 1H), 2.16-2-03 (m, 1H), 1.95 (brs, 1H), 1.88-
1.77 (m, 1H), 1.70-1.58 (m, 1H), 1.04-0.93 (m, 1H).  
Note: N-(4-trifluoromethylbenzyl)cinchonidinium bromide is a well-known and used 
compound, but no NMR data could be found [19].  
HRMS (Q-TOF): m/z calculated for C26H27F2N2O [M]+ 421.2091, found: 421.2100. 
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N-(3-cyano)benzylcinchonidinium bromide 170b 
 
Following General Procedure II: cinchonidine (0.40 g, 1.36 mmol, 100 mol-%) and 3-
cyanobenzyl bromide (0.29 g, 1.49 mmol, 110 mol-%) gave the product as a white 
solid (reaction time 6h). Isolated yield 92%. 
13C NMR (DMSO, 400 MHz) δ ppm 150.1, 147.6, 145.1, 138.6, 138.0, 137.2, 133.7, 
130.1, 129.8, 129.6, 129.4, 127.3, 124.2, 123.7, 120.1, 118.4, 116.4, 112.0, 67.8, 
64.0, 61.3, 59.2, 50.7, 36.8, 25.8, 24.2, 21.0. 
1H NMR (DMSO, 400 MHz) δ ppm 8.99 (d, J = 4.3 Hz, 1H), 8.37-8.32 (m, 2H), 8.17 
(d, J = 7.6 Hz, 1H), 8.09 (dd, J = 14.9, 8.0 Hz, 2H), 7.88-7.72 (m, 4H), 6.81-6.71 (m, 
1H), 6.57-6.53 (m, 1H), 5.68 (ddd, J = 17.0, 10.5, 6.2 Hz, 1H), 5.36-5.17 (m, 3H), 4.95 
(d, J = 10.5 Hz, 1H), 4.41-4.30 (m, 1H), 4.00-3.92 (m, 1H), 3.92-3.83 (m, 1H), 3.37 (s, 
2H), 3.33-3.21 (m, 1H), 2.67 (brs, 1H), 2.17-1.97 (m, 2H), 1.87-1.75 (m, 1H), 1.33-
1.22 (m, 1H). 
HRMS (Q-TOF): m/z calculated for C27H28N3O [M]+ 410.2232, found: 410.2254. 
N-(3-nitro)benzylcinchonidinium bromide 171b 
 
Following General Procedure I: cinchonidine (0.5 g, 1.70 mmol) and 3-phenylbenzyl 
bromide (0.37 g, 1.70 mmol) gave the product as a slightly beige solid (reaction time 
10 h). Isolated yield 94%. 
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13C NMR (DMSO, 400 MHz) δ ppm 150.2, 148.0, 147.6, 145.1, 140.3, 138.0, 130.5, 
130.0, 129.8, 129.4, 128.5, 127.3, 124.9, 124.2, 123.7, 120.1, 116.4, 67.9, 64.0, 61.2, 
59.1, 50.6, 36.9, 25.8, 24.2, 21.0. 
1H NMR (DMSO, 400 MHz) δ ppm 9.00 (d, J = 4.3 Hz, 1H), 8.72 (s, 1H), 8.43 (d, J = 
7.8 Hz, 1H), 8.36 (d, J = 8.2 Hz, 1H), 8.28 (d, J = 7.4 Hz, 1H), 8.12 (d, J = 8.3 Hz, 1H), 
7.93-7.74 (m, 4H), 6.81-6.76 (m, 1H), 6.63-6.55 (m, 1H), 5.68 (ddd, J = 17.0, 10.4, 
6.4 Hz, 1H), 5.45 (d, J = 12.2 Hz, 1H), 5.33 (d, J = 12.2 Hz, 1H), 5.24-5.15 (m, 1H), 
4.96 (d, J = 10.6 Hz, 1H), 4.44-4.34 (m, 1H), 4.02-3.86 (m, 2H), 3.40-3.24 (m, 2H), 
2.70-2.60 (m, 1H), 2.19-1.97 (m, 3H), 1.86-1.73 (m, 1H) 1.35-1.24 (m, 1H). 
HRMS (Q-TOF): m/z calculated for C26H28N3O3 [M]+ 430.2131, found: 430.2131. 
1,3-Bis(cinchonidinium-N-methyl)benzyl dibromide 172 
 
To a flask equipped with a magnetic stirring bar and a reflux condenser was added 
cinchonidine, (1.00 g, 3.39 mmol, 200 mol-%), dry THF (34 ml (0.1 M)), and 1,3-
bis(bromomethyl)-benzene (0.448 g, 1.70 mmol, 100 mol-%). The mixture was heated 
to reflux until judged to be complete by LC-MS-analysis (10h). The mixture was then 
cooled to room temperature and MTBE was added (70 ml). The resulting suspension 
was stirred for 1h at room temperature and the precipitated solids were isolated by 
filtration, yielding the product as a beige solid in a 98% yield. 
13C NMR (DMSO, 400 MHz) δ ppm 150.1, 147.6, 145.1, 138.9, 138.1, 135.3, 129.6, 
128.6, 127.4, 124.2, 123.7, 120.2, 116.2, 67.6, 64.2, 62.1, 59.1, 50.5, 36.7, 36.7, 25.8, 
24.1, 21.1. 
1H NMR (DMSO, 400 MHz) δ ppm 9.01 (d, J = 4.2 Hz, 2H), 8.39 (d, J = 8.2 Hz, 2H), 
8.18 (s, 1H), 8.12 (d, J = 8.3 Hz, 2H), 7.99 (d, J = 7.4 Hz, 2H), 7.90-7.73 (m, 7H), 
6.82-6.76 (m, 2H), 6.64-6.58 (m, 2H), 5.69 (ddd, J = 16.9, 10.3, 6.3 Hz, 2H), 5.39-
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5.16 (m, 6H), 4.96 (d, J = 10,4 Hz, 2H), 4.39-4.27 (m, 2H), 4.06-3.78 (m, 4H), 3.69-
3.55 (m, 2H), 2.78 (m, 2H), 2.19-1.79 (m, 10H), 1.37-1.21 (m, 2H).  
HRMS (Q-TOF): m/z calculated for C46H51N4O2 [M-H]+ 691.4012, found: 691.3931. 
1,4-Bis(cinchonidinium-N-methyl)benzyl dibromide 173 
 
To a flask equipped with a magnetic stirring bar and a reflux condenser was added 
cinchonidine, (1.00 g, 3.39 mmol, 200 mol-%), dry THF (34 ml, 0.1 M), and 1,3-
bis(bromomethyl)-benzene (0.448 g, 1.70 mmol, 100 mol-%). The mixture was heated 
to reflux until the reaction did not seem to precede further (5.5h). The mixture was 
then cooled to room temperature and MTBE was added (70 ml). The resulting 
suspension was stirred for at least 1h and the precipitated solids were isolated by 
filtration. The crude product was purified by flash column chromatography (0-20% 
MeOH in CH2Cl2 used as eluent, fractions containing product at approximately 15%). 
The fractions containing the product were combined yielding the product as a peach 
colored solid in a 46% yield. 
13C NMR (DMSO, 400 MHz) δ ppm 150.2, 147.6, 145.3, 138.3, 134.1, 129.9, 129.8, 
129.5, 127.3, 124.3, 123.7, 120.1, 116.2, 67.6, 64.2, 62.1, 59.1, 50.5, 36.6, 25.9, 24.1, 
21.2. 
1H NMR (DMSO, 400 MHz) δ ppm 9.00 (d, J = 4.5 Hz, 2H), 8.37 (d, J = 8.4 Hz, 2H), 
8.12 (dd, J = 8.4, 1.1 Hz, 2H), 7.93 (s, 4H), 7.90-7.82 (m, 4H), 7.81-7.75 (m, 2H), 
6.78-6.74 (m, 2H), 6.63-6.55 (m, 2H), 5.68 (ddd, J = 17.1, 10.6, 6.3 Hz, 2H), 5.31-
5.15 (m, 6H), 4.95 (d, J = 10.6 Hz, 2H), 4.33-4.21 (m, 2H), 4.00-3.91 (m, 2H), 3.87-
3.75 (m, 4H), 3.59-3.49 (m, 2H),2.89-2.80 (m, 2H), 2.16-2.06 (m, 2H), 2.04-1.92 (m, 
6H), 1.32-1.21 (m, 2H).  
HRMS (Q-TOF): m/z calculated for C46H51N4O2 [M-H]+ 691.4012, found: 691.3940. 
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Chiral tetraaminophosphonium chloride 174 
 
Chiral tetraaminophosphonium chloride 174 was prepared according to the procedure 
reported by Ooi and co-workers. [30] 
The chiral tetraaminophosphonium chloride 174 was prepared by dissolving (1S,2S)-
(-)-1,2-diamino-1,2-diphenylethane (0.500 g, 2.353 mmol, 200 mol-%) in 
dichloromethane (6 ml, 0.4 M). Phosphorus pentachloride (0.245 g, 1.177 mmol, 100 
mol-%) was added to the reaction mixture portion wise. The mixture was placed under 
a nitrogen atmosphere before the addition of pyridine (1.9 ml, 24.1 mmol, 20.5 eq). 
The reaction mixture was stirred for 2h before the addition of triethylamine (1.6 ml, 
11.8 ml, 10 eq). The reaction mixture was stirred for another 3h before all volatiles 
were evaporated from the reaction mixture. The remainder was triturated with 1M 
aqueous hydrochloric acid solution (5.5 ml) and the remaining solids were washed 
with methyl tert-butyl ether. The crude product was purified by flash column 
chromatography using methanol and dichloromethane (0-20%) as eluent. The chiral 
tetraminophosphonium chloride 174 was obtained as a solid (0.205 g, 36%). 
1H NMR (CD3OD, 400 MHz) δ ppm 7.41 - 7.29 (m, 20H), 4.54 (d, J = 3.3 Hz, 4H). 
The 1H NMR results corresponded to those reported in literature. [30] 
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Chiral tetraaminophosphonium chloride 65a 
 
Chiral tetraaminophosphonium chloride 65a was prepared according to the procedure 
reported by Ooi and co-workers with some minor variations [30] 
Chiral tetraaminophosphonium chloride 65a was prepared by dissolving the chiral 
tetraaminophosphonium chloride 174 (0.180 g, 0.370 mmol, 1 eq) obtained from the 
reaction above in dry N,N-dimethyl formamide (7.4 ml, 0.05 M). To this solution benzyl 
bromide (0.44 ml, 3.7 mmol, 10 eq) was added. A suspension of sodium hydride 
(0.089 g, 3.70 mmol, 10 eq) and acetonitrile (3.7 ml, 1 M) was created by cooling the 
acetonitrile to 0 ºC and adding the sodium hydride to it in portions. The mixture was 
kept on the ice bath and put under a nitrogen atmosphere. The mixture containing the 
chiral tetraaminophosphonium chloride 174 was added to the sodium hydride 
suspension drop wise. The mixture was stirred at room temperature overnight. The 
reaction was monitored using UPLC-MS analysis, and when no starting material could 
be detected, the reaction mixture was cooled to 0 ºC using an ice bath, before adding 
ethanol (8 ml) drop wise to the mixture. The mixture was stirred in the ice bath for an 
hour. Volatiles were evaporated and the remainder was diluted with dichloromethane 
and washed with 1 M aqueous hydrochloric acid solution. The organic phase was 
dried over sodium sulfate and solvents were evaporated. The crude product was 
purified by flash column chromatography using methanol and dichloromethane (0-
20%). A white powder (0.159 g, 51%) was obtained. 
1H NMR (CDCl3, 400 MHz) δ ppm 7.39 - 7.28 (m, 16H), 7.26 - 7.21 (m, 8H), 7.13 - 
7.07 (m, 8H), 6.95 - 6.90 (d, J = 7.5 Hz, 8H), 4.78 (s, 4H), 4.26 (dd, J = 15.3, 12.8 Hz, 
4H), 3.94 (t, J = 15.2 Hz, 4H). 
The 1H NMR results corresponded to those reported in literature. [30] 
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Chiral tetraaminophosphonium chloride 45a 
 
Chiral tetraaminophosphonium chloride 45a was prepared according to the procedure 
reported by Ooi and co-workers [26] with some minor variations (Scheme 68). The 
first variation was that the (S)-2-amino-3-methyl-1,1-diphenylbutan-1-ol was not made 
into a hydrochloric acid before aziridination. The second change was that platinum 
(IV) oxide was used instead of palladium. This was done because in the first batch 
the UPLC-MS analysis results indicated a broad spectrum of products, probably over-
hydrogenated products. 
 
Scheme 68. Chiral tetraaminophosphonium chloride preparation. 
 
(S)-1-azido-3-methyl-1,1-diphenylbutan-2-amine was prepared by cooling 
trifluoroacetic acid (10 ml, 0.2 M) to 0ºC, before adding sodium azide (0.636 g, 9.79 
mmol, 100 mol-%) in a portion wise manner to a 50 ml round-bottomed flask. (S)-2-
amino-3-methyl-1,1-diphenyl-1-butanol (0.500 g, 1.958 mmol, 500 mol-%) was added 
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to the solution in a portion wise manner. The reaction mixture was stirred for 6h at 
room temperature before it was poured onto crushed ice. The resulting mixture was 
stirred vigorously. Sodium hydroxide pellets were added to the mixture until a pH of 
11-12 was achieved. The resulting mixture was extracted with ethyl acetate (3 x 50 
ml) and the combined organic phases were washed with brine (2 x 50 ml) and dried 
over sodium sulfate. The solvents were evaporated yielding colorless oil (0.549 g, 
97%). The product was used for the next step without purification. 
 
(S)-3-methyl-1,1-diphenylbutan-1,2-diamine was prepared by adding the (S)-1-azido-
3-methyl-1,1-diphenylbutan-2-amine (0.549 g, 1.712 mmol, 100 mol-%) obtained from 
the previous reaction to ethanol (8.6 ml, 0.2 M) in a 50 ml round-bottomed flask. 
Platinum-(IV)oxide (0.019 g, 0.086 mmol, 5 mol-%) was added to the mixture and the 
atmosphere was replaced with hydrogen. The reaction mixture was stirred at room 
temperature. The reaction was monitored by UPLC-MS analysis, and when judged to 
be complete, approximately 4h after initiation, the hydrogenation was terminated and 
active charcoal (0.076 g) was added to the mixture. The resulting mixture was stirred 
for 15 minutes before being filtered through a pad of Celite®. The solvents were 
evaporated from the filtrate yielding the crude product as a yellow liquid with white 
solids. The crude product was purified by flash column chromatography using a large 
silica column (24 g) and as eluents methanol and ethyl acetate (0-10%) were used. 
The product isolated was a white solid (0.326 g, 75%). 
1H NMR (CDCl3, 400 MHz, δ ppm 7.51 - 7.42 (m, 4H), 7.32 - 7.25 (m, 4H), 7.22 - 7.15 
(m, 2H), 3.67 (d, J = 1.8 Hz, 1H), 1.93 - 1.79 (m, 1H), 0.99 (d, J = 6.9 Hz, 3H), 0.75 
(d, J = 6.7 Hz, 3H). 
 
Chiral tetraaminophosphonium chloride 45a was prepared by dissolving phosphorus 
pentachloride (0.147 g, 0.706 mmol, 100 mol-%) in toluene (3.5 ml, 0.2M). The (S)-3-
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methyl-1,1-diphenylbutan-1,2-diamine (0.326 g, 1.412 mmol, 200 mol-%) was 
dissolved in a separate round-bottomed flask in toluene (3.5 ml, 0.4 M) and 
triethylamine (0.49 ml, 3.53 mmol, 500 mol-%). The phosphorus pentachloride 
solution was added to the (S)-3-methyl-1,1-diphenylbutan-1,2-diamine mixture. The 
mixture monitored by UPLC-MS analysis under the refluxation and when judged to be 
complete, after approximately 2 h, the heating was seized. The solvent in the reaction 
mixture was evaporated, and the remainder was dissolved in dichloromethane (20 ml) 
and was washed with 1M aqueous hydrochloric acid solution (30 ml). The organic 
phase was dried over sodium sulfate and solvents were evaporated. The crude 
product was purified by flash column chromatography using methanol and 
dichloromethane (0-10%) as eluents. The product attained was a yellow solid (0.212 
g, 53%). 
1H NMR (CDCl3, 400 MHz) δ ppm 7.36 - 7.28 (m, 14H), 7.24 - 7.17 (m, 6H), 4.83 (br 
s, 1H), 4.79 (br s, 1H), 1.67 - 1.55 (m, 2H), 0.91 (d, J=6.5 Hz, 6H), 0.78 (d, J=6.7 Hz, 
6H). 
The 1H NMR results have been reported in literature. [26] 
Pentanidium chloride 175 
 
Chiral pentanidium chloride 175 was prepared according to the procedure reported 
by Tan and co-workers [50] with some minor variations. 
 
Step 1: (4S, 5S)-(-)-4,5-diphenylimidazolidin-2-one was prepared by dissolving (1S, 
2S)-(-)-1,2-diphenylethane (2.123 g, 10 mmol, 100 mol-%) and triethylamine (4.18 ml, 
30.0 mmol, 300 mol-%) in dry dichloromethane (25 ml, 0.4 M). The mixture was put 
under a nitrogen atmosphere and cooled to 0 ºC using an ice bath. 
Bis(trichloromethyl)carbonate (0.979 g, 3.30 mmol, 33 mol-%) was dissolved in dry 
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dichloromethane (5 ml, 0.66 M) and added to the mixture containing (1S, 2S)-(-)-1,2-
diphenylethane in a drop wise manner. The reaction was monitored using UPLC-MS 
analysis and when judged to be complete, approximately 4 h after initiation of reaction, 
the reaction was quenched with distilled water (20 ml). Phases were separated and 
the aqueous phase was extracted with dichloromethane (3 x 30 ml). The combined 
organic phases were washed with brine (80 ml) and dried over sodium sulfate. 
Solvents were evaporated and the yellow solid obtained (2.38 g, 100%) was used for 
the next step without further purification. 
 
Step 2: (4S,5S)-1,3-dimethyl-4,5-diphenylimidazolidin-2-one was prepared by 
creating a suspension of sodium hydride (0.720 g, 30.0 mmol, 3 eq) and dry 
tetrahydrofuran (15 ml, 2 M). The suspension was put under a nitrogen atmosphere 
and cooled in an ice bath. To this suspension, (4S,5S)-(-)-4,5-diphenylimidazolidin-2-
one (2.383 g, 10.00 mmol, 1 eq) dissolved in dry tetrahydrofuran (20 ml, 0.5 M) was 
added in a drop wise manner. The reaction mixture was stirred at room temperature 
for 15 minutes before being cooled to 0 ºC again. Iodomethane (2.3 ml, 37.0 mmol, 
3.7 eq) was added to the reaction mixture. The reaction mixture was monitored by 
UPLC-MS analysis and was stirred at room temperature until judged to be complete, 
approximately 3 h. The reaction mixture was filtered through a pad of Celite® and the 
pad was washed with a generous amount of tetrahydrofuran. Solvents were 
evaporated from the filtrate and the crude product was purified by flash column 
chromatography using ethyl acetate and heptane (0-100%) as eluents. The ((4S,5S)-
1,3-dimethyl-4,5-phenylimidazolidin-2-one was obtained as a yellowish solid (0.76 g, 
29%). 
1H NMR (CDCl3, 400 MHz) δ ppm 7.38 - 7.31 (m, 6H), 7.17 - 7.12 (m, 4H), 4.08 (s, 
2H), 2.70 (s, 6H). 
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Step 3: (4S,5S)-2-chloro-1,3-dimethyl-4,5-diphenyl-4,5.dihydro-1H-imidazol-3-ium 
was obtained by dissolving the (4S,5S)-1,3-dimethyl-4,5-phenylimidazolidin-2-one 
(0.76 g, 2.58 mmol, 1 eq) obtained in the previous step (step 2) in dry toluene (20 ml, 
0.13 M) under a nitrogen atmosphere. Oxalyl chloride (2.4 ml, 28.5 mmol, 10 eq) was 
added to the solution. The reaction mixture was refluxed overnight under a continuous 
nitrogen flow. The majority of the solvent had evaporated under night, so methyl tert-
butyl ether (20 ml) and toluene (2 ml) was added to the round-bottomed flask in the 
morning and the resulting mixture was stirred at room temperature for 3 h before being 
filtered under a nitrogen flow. The product was obtained as a gray brown solid (0.538 
g, 66%). 
 
Step 4: (4S,5S)-1,3-dimethyl-4,5-diphenylimidazoline-2-imine was prepared by 
dissolving half of the (4S,5S)-2-chloro-1,3-dimethyl-4,5-diphenyl-4,5.dihydro-1H-
imidazol-3-ium obtained in the previous step (step 3) in 2 M ammonia solution in 
methanol and poured into a round-bottomed pressure flask. The flask was put under 
a nitrogen atmosphere and sealed. The reaction mixture was heated to 60 ºC. The 
reaction mixture was heated overnight (approximately 19 h) and was cooled to room 
temperature in the morning. The pressure was released, and 40 ml of distilled water 
was added to the reaction mixture. The phases were separated and the aqueous 
phase was extracted with dichloromethane (3 x 20 ml). The combined organic phases 
were dried over sodium sulfate and solvents were evaporated yielding a brown 
crystalline solid (0.20 g, 80%). 
1H NMR (CDCl3, 400 MHz) δ ppm 7.39 - 7.31 (m, 6H), 7.17 - 7.12 (m, 4H), 4.08 (s, 
2H), 2.71 (s, 6H). 
 
Step 5: Chiral pentanidium chloride 175 was prepared by adding the remainder of 
(4S,5S)-2-chloro-1,3-dimethyl-4,5-diphenyl-4,5.dihydro-1H-imidazol-3-ium (0.269 g, 
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0.942 mmol, 100 mol-%) and triethylamine (0.14 ml, 1.00 mmol, 106 mol-%) to dry 
acetonitrile (15 ml, 0.06 M). To this mixture the (4S,5S)-1,3-dimethyl-4,5-
diphenylimidazoline-2-imine (0.20 g, 0.754 mmol, 80 mol-%) dissolved in dry 
acetonitrile (3 ml, 0.25 M) was added. The reaction mixture was stirred overnight. 
When judged to be complete, the reaction mixture was quenched with water (20 ml) 
and the resulting phases were separated. The aqueous phase was extracted using 
dichloromethane (3 x 20 ml). The combined organic phases were dried over sodium 
sulfate and solvents were evaporated. The crude product was purified by flash column 
chromatography using methanol and dichloromethane (0-20%) as eluents. Chiral 
pentanidium chloride 175 was obtained as a white solid (0.0236 g, 4.6%). 
1H NMR (CDCl3, 400MHz) δ ppm 7.43 - 7.34 (m, 12H), 7.29 - 7.25 (m, 8H), 4.72 (s, 
4H), 2.98 (s, 12H). 
The 1H NMR results corresponded to those reported in literature. [50] 
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Appendix 5: N-(3-phenyl)benzylcinchonidinium bromide 163b 
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Appendix 6: N-(3,5-methyl)benzylcinchonidinium bromide 
164b 
 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
0
.0
0
0
0
0
.0
7
3
9
1
.0
0
9
5
1
.0
1
4
7
1
.8
4
3
1
1
.8
5
1
9
1
.8
7
7
9
1
.8
9
1
6
2
.0
3
6
8
2
.1
3
3
6
2
.2
1
3
1
2
.4
7
4
8
2
.4
8
1
9
3
.1
3
0
1
3
.1
5
6
7
3
.1
6
2
1
3
.1
8
9
1
3
.8
7
2
8
3
.9
0
5
3
4
.1
2
4
7
4
.8
8
6
3
4
.8
8
9
3
4
.9
1
2
3
4
.9
1
5
1
5
.2
6
5
9
5
.3
0
9
1
5
.3
1
0
8
5
.3
7
7
5
5
.3
9
2
2
5
.4
0
2
7
5
.4
1
8
3
5
.4
3
0
7
5
.8
5
1
9
5
.8
8
1
5
6
.4
7
8
2
6
.4
8
4
7
6
.4
9
1
9
6
.4
9
7
8
6
.5
9
0
1
6
.6
0
5
0
6
.8
2
2
8
7
.1
6
5
9
7
.1
7
0
2
7
.1
7
9
8
7
.1
8
9
6
7
.1
9
3
7
7
.2
7
9
3
7
.2
9
5
3
7
.6
4
9
6
7
.6
5
4
2
7
.6
6
1
3
7
.6
6
4
4
7
.6
6
7
5
7
.6
7
3
9
7
.8
1
1
7
7
.8
2
2
8
8
.1
5
0
2
8
.1
5
6
5
8
.1
6
0
0
8
.1
6
2
4
8
.1
7
0
3
8
.1
7
4
3
8
.7
9
8
0
0
.9
9
1
.0
1
2
.1
0
1
.0
7
0
.3
7
6
.1
0
1
.0
4
2
.0
2
0
.9
9
1
.0
0
1
.0
0
1
.0
0
1
.0
1
2
.0
4
0
.9
8
0
.9
7
1
.0
1
1
.0
1
2
.0
1
2
.2
2
1
.0
0
1
.0
1
0
.9
9
1
.0
0
D15-3129 AAH-002-72_CDCl3
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
2
1
.3
4
2
2
.4
9
2
5
.2
2
2
6
.5
5
3
7
.9
7
5
0
.4
5
6
0
.2
3
6
2
.4
4
6
5
.2
0
6
6
.8
2
7
6
.8
4
7
7
.1
6
7
7
.4
8
1
1
7
.8
5
1
1
9
.8
9
1
2
3
.1
9
1
2
3
.7
8
1
2
6
.9
2
1
2
7
.3
7
1
2
8
.4
8
1
2
9
.6
3
1
3
1
.5
7
1
3
1
.6
1
1
3
6
.1
8
1
3
8
.2
4
1
4
4
.7
4
1
4
7
.2
8
1
4
9
.5
7
D15-3129 AAH-002-72_CDCl3
  
Appendix 7: N-(2,4-methyl)benzylcinchonidinium chloride 
165b 
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Appendix 8: N-(4-isopropyl)benzylcinchonidinium bromide 
167b 
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Appendix 9: N-(trifluoromethyl)benzylcinchonidium bromide 22b 
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Appendix 10: N-(4-chloro-[2-trifluoromethyl])benzylcinchonidinium 
bromide 168b 
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Appendix 11: N-(3,4-difluoro)benzylcinchonidinium bromide 169b 
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Appendix 12: N-(3-cyano)benzylcinchonidinium bromide 170b 
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Appendix 13: N-(3-nitro)benzylcinchonidinium bromide 171b 
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Appendix 14: 1,3-Bis(cinchonidinium-N-methyl)benzyl dibromide 
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Appendix 15: 1,4-Bis(cinchonidinium-N-methyl)benzyl dibromide 
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Appendix 16: Enantioselectivity method (HPLC) 
Racemate: 
 
 
 
 
  
  
Sample: 
 
 
 
  
  
Appendix 17: Enantioselectivity method (UPC2 – supercritical 
CO2) 
Racemate: 
 
Sample: 
 
